

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Intermittent pneumatic compression for venous thromboembolism prevention: a systematic review on factors affecting adherence

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-037036
Article Type:	Original research
Date Submitted by the Author:	20-Jan-2020
Complete List of Authors:	Greenall, Richard; King's College Hospital NHS Foundation Trust, Executive Offices, Princess Royal University Hospital, Farnborough, BR6 8ND Davis, Rachel; King's College London, Centre for Implementation Science , Health Services and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience
Keywords:	Thromboembolism < CARDIOLOGY, Bleeding disorders & coagulopathies < HAEMATOLOGY, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Intermittent pneumatic compression for venous thromboembolism prevention: a**  
4 **systematic review on factors affecting adherence**  
5  
6  
7

8 **Authors**  
9

10 Richard Greenall, BSc, MSc<sup>1</sup>

11 Rachel Davis, BSc, MSc, PhD<sup>2</sup>

12  
13 <sup>1</sup>King's College Hospital NHS Foundation Trust

14 Executive Offices

15 Princess Royal University Hospital

16 Farnborough

17 BR6 8ND

18 Email: writetorichg@gmail.com

19  
20  
21 Centre for Implementation Science

22 <sup>2</sup>Health Services and Population Research Department,

23 Institute of Psychiatry, Psychology and Neuroscience

24 King's College London

25 2nd Floor, Room E2.19

26 16 De Crespigny Park

27 Denmark Hill

28 LONDON

29 SE5 8AF

30 Email: [rachel.davis@kcl.ac.uk](mailto:rachel.davis@kcl.ac.uk)  
31  
32

33  
34 Corresponding author: Richard Greenall  
35  
36

37 **Competing interests**

38 None declared  
39

40 **Contributorship statement**

41 RG and RD designed the paper and were responsible for its conceptualisation. RG drafted the paper  
42 and RD edited it. Both authors were involved in the screening of the articles included in the review  
43 and have read and approved the final version of the manuscript.  
44

45 **Funding**

46 Rachel Davis is supported by the National Institute for Health Research (NIHR) Applied Research  
47 Collaboration South London (NIHR ARC South London) at King's College Hospital NHS Foundation  
48 Trust. The views expressed are those of the author[s] and not necessarily those of the NIHR or the  
49 Department of Health and Social Care.  
50  
51

52 **Data sharing statement**

53 All data generated or analysed during this study are included in this published article (and its  
54 supplementary information files).  
55

56 **Word count;** 4270  
57  
58  
59  
60

## Abstract

**Objective** Venous thromboembolism (VTE) is a potentially fatal complication of hospitalisation. Intermittent pneumatic compression (IPC) is one approach to reducing the likelihood of a VTE. Adherence to IPC is known to be inadequate though the reasons for this remain unclear. This systematic review explores factors that affect adherence to IPC in the inpatient context.

**Methods** EMBASE, MEDLINE and PsycINFO were searched for literature between 1960-2019. Studies were included if they focused on inpatient care and examined factors affecting adherence to IPC devices.

**Results** A total of 20 out of 1476 studies were included. Eight factors were identified that affected adherence: patient discomfort (n=8), healthcare professionals' knowledge and behaviours (n=6), mobilisation (n=6), equipment supply and demand (n=3), the use of guidelines (n=3), intensive care context (n=2), computer-assisted prescribing (n=2) and patients' knowledge of IPC (n=1).

**Conclusion** Overall while the evidence base is quite limited, a number of factors were shown to affect adherence to IPC. These findings could be used to inform future research and quality improvement efforts to increase adherence in this very important, but currently under-researched area.

**Keywords;** Intermittent pneumatic compression, adherence, compliance, thromboprophylaxis, venous thromboembolism, VTE, deep vein thrombosis, pulmonary embolism

## Strengths and limitations

- First known review of the evidence affecting adherence to IPC
- Eight factors were identified that resulted in measurable changes to adherence to IPC
- Results largely based on direct observation rather than self-report
- Studies generally had low sample sizes
- Studies with different aims and methodologies were included.

## Background

Venous thromboembolism (VTE) is a term that most commonly refers to deep vein thrombosis (DVT) and pulmonary embolism (PE). VTE affects 1 in 1000 people annually<sup>(1)</sup> and in England in 2018 VTE was recorded as a cause of death in 12,000 cases<sup>(2)</sup>. Compared to baseline risk, hospitalisation has been correlated with an 8-fold increased risk of VTE in medical admissions and a 21-fold increased risk in surgical admissions<sup>(3)</sup> with one study estimating that up to 50% of 625 cases of VTE in the community were related to hospitalisation<sup>(4)</sup>. Secondary to adverse drug events, VTE is the leading complication of hospitalisation worldwide<sup>(5)</sup>.

The financial cost of hospital associated VTE is high. In 2017, a UK survey revealed the average cost of treating VTE was £938,357 for each local NHS region<sup>(6)</sup>. At a patient level, a review<sup>(7)</sup> identified an increase in cost of \$14,000 for initial diagnosis and the first year of treatment for those with VTE compared with non-VTE affected patients. VTE can have a significant impact on a person's psychosocial well-being with research to suggest that it can be a traumatic, life-changing event which can lead to post traumatic stress disorder<sup>(8,9)</sup>.

Since hospitalisation increases the risk of VTE, it is important to consider if anything can be done to reduce the risk within this context. In England, the national VTE prevention programme combined a mandate for assessment of patient's risk on admission to hospital with best practice prevention guidelines. Early results indicate that its efforts have led to reduced morbidity and mortality<sup>(10)</sup>. Similar efforts have been made in the USA<sup>(11)</sup> and throughout Europe, recent evidence indicates that better management of the risk of VTE has reduced VTE related mortality from 12.8 to 6.5 deaths per hundred thousand<sup>(12)</sup>.

Risk assessing all patients on admission to hospital leads to identification of patients at high risk who need thromboprophylaxis (i.e. treatments to prevent VTE). In the UK, national guidelines<sup>(13)</sup> advise using the chemical thromboprophylaxis low molecular weight heparin for most groups of at-risk hospitalised patients. Mechanical thromboprophylaxis is advised for most surgical patients and other

1  
2  
3 high-risk groups, such as patients with stroke. Graduated compression stockings (GCS) are one type of  
4 mechanical intervention. GCS exerts graded pressure around the legs, increasing the speed of blood  
5 flow and reducing the opportunity for VTE to form.  
6  
7  
8  
9

10 Intermittent pneumatic compression (IPC) is another type of mechanical device. Fabric sleeves that  
11 wrap around a patient's legs are attached to a pump using a tube and are periodically inflated and  
12 deflated. IPC is thought to reduce VTE by increasing the speed of blood flow and reducing  
13 hypercoagulability through the IPC action stimulating the vessel walls fibrinolytic activity<sup>(14,15)</sup>.  
14 Combining IPC and GCS decreases the incidence of VTE to a greater effect than either individually<sup>(16)</sup>  
15 and a systematic review found that that IPC can reduce the incidence of VTE in surgical patients (risk  
16 ratio 1.39, CI 0.73-2.64)<sup>(17)</sup>. However, despite these benefits, research has shown considerable  
17 variability in adherence to IPC device use, with a systematic review of 7 studies in acute hospitals  
18 reporting a median adherence rate of 78% (range 40%-89%)<sup>(18)</sup>. The authors concluded that strategies  
19 to improve adherence are needed but the question remains as to why non-adherence occurs.  
20  
21  
22  
23  
24  
25  
26  
27

28 To the best of our knowledge, no attempt has been made to comprehensively investigate the factors  
29 that could facilitate or impede adherence to IPC. This paper aims to address this important gap in the  
30 evidence base by systematically reviewing the factors that influence adherence to IPC for VTE  
31 prevention in acute care. Gaining this understanding is critical in order to develop interventions,  
32 strategies and policies that are accurately targeted at meeting the challenges of improving  
33 adherence<sup>(19)</sup>.  
34  
35  
36  
37  
38  
39  
40  
41

## 42 **Methods**

### 43 *Patient and public involvement*

44  
45 No patient involved  
46  
47  
48  
49

### 50 *Search strategy*

51 EMBASE, MEDLINE and PsycINFO were searched for relevant literature published between 1960 -  
52 2019. The search strategy comprised terms relating to: 1) population (e.g. 'IPC'); 2) Intervention (e.g.  
53 'strategies') and; 3) outcomes (e.g. 'adherence'). The search was customized to each database and  
54 restricted to titles and abstracts to tighten its specificity. A sensitivity analysis was performed to  
55 ensure the search results included key articles identified through an initial scoping review. Forward  
56  
57  
58  
59  
60

1  
2  
3 and backward citation searching and hand searching of key journals were performed to minimize the  
4 likelihood of missing relevant papers. The final search was conducted on 30th May 2019 (for the full  
5 search strategy please refer to Supplementary file 1).  
6  
7  
8  
9

### 10 *Inclusion criteria*

11 Based on UK national guidelines that were current at the time of this review's development (January  
12 2018)<sup>(13)</sup>, the definition of IPC in this review includes only devices that are applied to the legs and  
13 excludes foot compression devices. The first stage of screening (title and abstract) was intentionally  
14 inclusive and retained any empirical articles that mentioned adherence to IPC in any context. In the  
15 second stage (full text), tighter restrictions applied. Articles were included if they reported barriers or  
16 facilitators to adherence to IPC in the inpatient context and included a measure of the effect  
17 (percentage change in adherence to IPC) of such factors on adherence (either as a primary or  
18 secondary aim or an indirect finding in the results). Dissertations and doctoral theses, books, book  
19 reviews, conference posters and presentations, editorials and commentaries were excluded, as were  
20 articles not published in English or those focused on patients under 18 years of age.  
21 Review/commentary papers that addressed adherence to IPC<sup>(18)</sup> were examined for relevant empirical  
22 papers but the reviews themselves were excluded.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

### 33 *Study selection and data extraction*

34 Articles were screened for relevance by the lead author (RG). The second author (RD) screened 20%  
35 of the articles at abstract stage and 100% at full-text stage. Discrepancies were resolved through joint  
36 discussion between the authors. Dual data extraction of the included articles was conducted  
37 independently by both authors and then checked for consistency.  
38  
39  
40  
41  
42

### 43 *Quality Assessment*

44 While numerous scales are available to assess the methodological quality of studies, these are often  
45 restricted to specific study designs, including randomised controlled trials<sup>(20)</sup>; case-control and cohort  
46 studies<sup>(21)</sup>; and qualitative studies<sup>(22)</sup>. Given our review included articles that employed heterogeneous  
47 study designs and differing aims, we did not use a quality assessment scale, nor did we deem this  
48 meaningful. We did however consider differences in the methodologies that could potentially bias the  
49 findings to enable greater understanding of the relative strengths and weaknesses of the research. To  
50 gain a comprehensive understanding of the full body of evidence, we did not exclude articles based  
51 on their methodological quality.  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Results

### *Study selection*

Of 1476 articles retrieved, 1324 were excluded at the first stage of screening (title/abstract) and 132 (out of the remaining 152) were excluded after full-text screening, resulting in 20 articles. Two of the included articles were added through handsearching<sup>(23,24)</sup> (see Figure 1). Upon examination, these studies were missed in the initial search due to the use of the word 'external' instead of 'intermittent' to describe pneumatic compression. Further scoping the literature (using the term 'external') revealed there were no other additional articles that needed to be included.

Insert Figure 1 here

### *Characteristics of included studies*

Articles were published between 1992 and 2018 across 6 countries, including the USA (n= 15<sup>(23-37)</sup>), Spain (n= 1<sup>(38)</sup>), Japan (n=1<sup>(39)</sup>), Canada (n=1<sup>(40)</sup>), France (n=1<sup>(16)</sup>) and Brazil (n=1<sup>(41)</sup>). Characteristics of patients and care locations included critical care<sup>(16,24,27,38,39)</sup>, general surgical wards<sup>(26,31-33,36,40,41)</sup> and gynaecology<sup>(23,34,35,37)</sup> specialties. Factors affecting adherence to IPC was the primary focus of 13 studies<sup>(23,25-32,34,35,37,38)</sup>. A further 7 studies<sup>(16,24,33,36,39-41)</sup> focused on IPC device safety and effectiveness in preventing VTE but also reported barriers or facilitators to IPC adherence. Seventeen of the studies were observational<sup>(24-39,41)</sup>, using surveys and clinical observations as investigation tools. The remaining three studies were RCTs<sup>(16,23,40)</sup>. Due to wide heterogeneity in study methodologies, meta-analysis was not possible. Table 1 details the characteristics of the included studies.

Insert table 1 here

### **Factors affecting adherence to IPC**

Articles varied considerably in the level of content and detail provided regarding study designs and adherence to IPC. We report the main findings here and provide a more detailed analysis of findings for studies where this was possible. Table 2 outlines the 8 factors that were identified that affected adherence to IPC.

Insert table 2 here

#### *1. Patient discomfort*

1  
2  
3 Patient discomfort associated with wearing the IPC device was identified in 8 studies<sup>(16,25,26,28,29,33,37,40)</sup>.  
4 Vignon<sup>(16)</sup> identified poor adherence in 7% (14/204) of patients due to discomfort, noise and  
5 restlessness. Brady<sup>(28)</sup> observed the effect of the length of the IPC sleeve on comfort and subsequent  
6 non-adherence. Overall adherence was 29% (40/137) based on a one-off observation. Eighty-five  
7 percent of non-adherent users had been wearing thigh length (53%) or knee length (32%) sleeves.  
8 Discomfort was reported as a reason for non-adherence by 39% (58/149) of patients who were non-  
9 adherent. Those wearing thigh length sleeves reported double the number of complaints compared  
10 to those wearing knee length sleeves (39 vs 15).

11 Brady<sup>(37)</sup> examined adherence over several days post-operatively. Taking multiple observations of the  
12 same patients, adherence was 75% (43/57) on day zero, 53% (148/278) on day 2, and 44% (11/25) on  
13 day 4. Patients who were non-adherent were asked why at the time of observation and 15% (53/362  
14 responses) stated discomfort as a reason. Kim<sup>(25)</sup> compared two groups of 100 patients in a  
15 multifaceted improvement strategy to increase adherence to IPC. Post intervention a slight  
16 improvement was achieved (24% versus 26%). Ninety-two percent of nurses (58/63) and 29% (4/14)  
17 of non-adherent patients reported discomfort as a reason for the lack of adherence.

18 Ritsema<sup>(26)</sup> found that patients were non-adherent 21% of the time (98/457 observations) with patient  
19 interviews indicating that discomfort was a reason in 19% (19/100) of responses. Sobieraj-Teague<sup>(40)</sup>  
20 trialled the efficacy of a newly developed IPC machine which allowed the patient to mobilise  
21 independently of a power cable through the utilisation of batteries and small product design. Poor  
22 adherence was found in 49% of users (35/72), in particular at night, with patients reported they  
23 discontinued therapy due to insomnia. Similar findings, but to a much lesser extent were reported by  
24 Cindolo<sup>(29)</sup> when evaluating the comfort and tolerability of a specific IPC device. While non-  
25 adherence was only 3% (6/184), patients who requested discontinuation of IPC therapy did so due to  
26 noise and insomnia.

27 A final study by Obi<sup>(33)</sup> was designed as a retrospective review examining whether a different design  
28 of IPC device would reduce non-adherence. Comparing a standard machine to a new machine,  
29 adherence to the standard machine was 47% versus 85% for the newer machine. Of responses from  
30 those patients wearing the standard compared to the new machine (21 and 24 respectively), problems  
31 with discomfort as reported less (33% vs. 13%).

## 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

### 2. Healthcare professional knowledge and behaviours

Failure of healthcare professionals to apply or provide IPC when prescribed was identified in 6  
studies<sup>(23,28,30,31,36,37)</sup>. Brady<sup>(28)</sup> found that 16% (12/73) of survey respondents reported that the nurse

1  
2  
3 had never initiated IPC therapy or had not replaced the sleeves after transfer of the patient from  
4 another location. Brady<sup>(37)</sup> found that 23% (82/356) of non-adherent patients stated the nurse had  
5 informed them that they did not require IPC anymore.  
6  
7

8 Cornwell<sup>(36)</sup> observed adherence of 53% (out of 712/1343 observations of 233 patients). The authors  
9 reported that this was because the device was 'not in place'. The time of day that non-adherence was  
10 most frequently noted was in the early afternoon and the authors concluded that it is both HCPs and  
11 patients who need to be educated about the importance of wearing IPC as the patient may have been  
12 the one who removed it.  
13  
14

15 Elphern<sup>(30)</sup> reported that errors in the application of IPC therapy were identified in 49% (477/966) of  
16 observations of a cohort of 123 patients. In 244 observations the sleeves were incorrectly applied to  
17 the patient and in 116 observations the pump was not turned on. Similar findings by Maxwell<sup>(23)</sup> in 104  
18 patients identified that the reason for non-adherence in 3% (20/736) of observations was that the IPC  
19 was not turned on. Gardiner<sup>(31)</sup> reported that only 26% (89/339) of patients were adherent to IPC on  
20 initial audit. A survey of nursing beliefs, practice and knowledge determined that part of the problem  
21 was deficiencies in nursing knowledge. Education interventions as well as placing IPC machines in  
22 individual rooms of patients improved adherence from 26% to 44%.  
23  
24  
25  
26  
27  
28  
29  
30  
31

### 32 3. Mobilisation

33 Issues relating to mobilisation were identified as factors affecting adherence in 6 studies<sup>(26,28,33,34,37,38)</sup>.  
34 Brady<sup>(28)</sup>, found that of 149 responses from non-adherent patients, 46% (68/149) of patients reported  
35 that they had just mobilised. Similarly, Brady<sup>(37)</sup> found that 16% (59/362) of patients reported that  
36 they had just been walking around, 17% (62/362) stated they had just returned to bed and 7% (24/362)  
37 were just about to walk around. In a study by Ritsema<sup>(26)</sup> previously discussed in relation to patient  
38 discomfort, patient's identified that not replacing the IPC sleeves after mobilisation was a cause of  
39 non-adherence in 50% of 98 non-adherent episodes observed.  
40  
41  
42  
43  
44

45 Palmerola<sup>(34)</sup> found adherence to IPC after caesarean delivery was 79.5% (233/293). Of the 60 non-  
46 adherent patients, 62% (37/60) had the IPC machine and sleeves in the room but they were not  
47 applied and 38% (23/60) had it discontinued due to "*liberal standards for mobilisation*". A study by  
48 Obi<sup>(33)</sup> previously discussed in relation to 'patient discomfort' found that problems with mobilising  
49 were reported less using a new machine compared to a standard one (71% vs. 29%). Garcia Olivares<sup>(38)</sup>  
50 found that complete bed rest for >2 days resulted in improved appropriateness of prophylaxis (OR  
51 0.6) with similar findings reported for mechanical ventilation (OR 0.7).  
52  
53  
54  
55  
56  
57

### 58 4. Equipment supply and demand

59  
60

1  
2  
3 Three studies<sup>(26,31,37)</sup> highlighted that equipment supply and demand could affect adherence. Brady<sup>(37)</sup>  
4 identified that part of the IPC device was not present in the room in 13% (49/362) of non-adherent  
5 episodes although reasons why were not explored. Similar findings by Ritsema<sup>(26)</sup> found that the  
6 second most commonly report reason for non-adherence was no machine or sleeves being available  
7 to the patient (22/100 questionnaire responses). As previously discussed within 'healthcare  
8 professionals knowledge and behaviours', a study by Gardiner<sup>(31)</sup> revealed that of 250 patients who  
9 were non-adherent, 39% (97/250) did not have part of the equipment in the room. This same study  
10 found that adherence increased from 26% to 44% through an educational intervention and making  
11 IPC machines widely available instead of difficult to obtain for use.  
12  
13  
14  
15  
16  
17  
18  
19

### 20 5. Guidelines

21 The use of guidelines for VTE prevention was identified as a factor that could affect adherence in 3  
22 studies<sup>(38,39,41)</sup>. Garcia Olivares<sup>(38)</sup> used an electronic questionnaire to investigate inappropriateness of  
23 VTE prophylaxis (all types) on a single day across multiple ICUs. A total of 777 patients across 73 ICUs  
24 were included: the use of a protocol reduced inappropriate VTE prevention prescribing (OR 0.6) as  
25 well as a VTE risk scoring system (OR 0.4). Yammamoto<sup>(39)</sup> obtained data from 99 ICUs and included  
26 470 patients in their analysis. Hospitals using protocols had higher rates of prophylaxis provision than  
27 those who did not (89% vs. 80%) and this difference was mainly due to the increase in the combined  
28 use of anti-embolic stockings and IPC (26% vs. 15%). A similar effect was demonstrated by Maffei<sup>(41)</sup>  
29 who retrospectively analysed the accuracy of prescribing of VTE prophylaxis after the implementation  
30 of guidelines. Compared to before the implementation of guidelines, prescribing of IPC therapy  
31 increased from 26% to 32% after.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

### 42 6. Intensive care context

43 Care provision in the intensive care unit (ICU) context was identified by two studies as having an  
44 impact on adherence<sup>(24,27)</sup>. Comerota<sup>(24)</sup> examined 138 patients and found that adherence in the  
45 intensive care unit (ICU) setting was higher than elsewhere in the hospital (78% vs. 48%) but did not  
46 investigate reasons for this. A study by Bockheim<sup>(27)</sup> found adherence in the ICU context was 69%  
47 (52/75) compared to 40% (30/75) outside of the ICU. The authors concluded the reasons for this were  
48 likely to be multifactorial they did not empirically determine what these factors might be.  
49  
50  
51  
52  
53  
54

### 55 7. Computer-assisted prescribing

56 Computer-assisted prescribing was reported as a factor affecting adherence in 2 studies<sup>(32,35)</sup>. Chen<sup>(35)</sup>  
57 examined the long-term impact of automatic pre-orders for IPC on an electronic prescription system.  
58  
59  
60

1  
2  
3 Prior to the intervention, prescribing of IPC was carried out on 46% (denominator not reported) of  
4 patients. One year later, this had increased to 78% (59/76). IPC was only present in 71% (42/59) of  
5 patients who had been prescribed IPC and was only being used by 45% (19/42) of those patients. The  
6 authors concluded that the intervention had successfully increased prescribing of IPC but not overall  
7 adherence.  
8  
9

10  
11 Novis<sup>(32)</sup> utilised a similar approach but did not assess the impact of adherence to IPC at a patient level.  
12 Computer generated suggestions of pre-operative prophylaxis were provided to the clinician as a  
13 result of information entered about the risk of VTE to the patient. The result was a 40% increase in  
14 prescribing of IPC from 215 to 301 patients with an active prescription.  
15  
16  
17

### 18 19 20 *8. Patient knowledge*

21 A study by Kim<sup>(25)</sup> concluded that the information needs of patients were a factor affecting adherence.  
22 An initial survey found that 59% (32/54) of patients did not have IPC applied when prescribed. Several  
23 clinician-focused interventions were conducted, and a survey of patients a year later found that 62%  
24 (41/66) of patients requiring IPC therapy did not have it applied. From this, thirty percent (11/37) of  
25 patients reported that they did not know what a DVT is and 62% (23/37) reported that they had not  
26 been educated about IPC. The authors conclude that a lack of education is an important barrier to  
27 adherence however evidence to demonstrate that increasing education results in improved  
28 adherence was not presented.  
29  
30  
31  
32  
33  
34  
35

### 36 37 **Quality Assessment**

38 Seventeen<sup>(24-39,41)</sup> (out of the 20) articles included in the review were observational in nature. All of  
39 these studies (n=17) measured adherence to IPC by direct observation of researchers rather than  
40 based on self-report, which could have been subject to recall bias. Eight of these studies measured  
41 adherence twice daily<sup>(23,24,26,27,31,35,37,40)</sup>, 3 had a single observation point (the first day post  
42 operatively<sup>(29,34)</sup> and not reported<sup>(28)</sup>), 1<sup>(33)</sup> had hourly monitoring across a 24 hour period, and 1<sup>(16)</sup> did  
43 not report when they observed adherence, only that they did this. In addition to direct observations,  
44 data on factors affecting adherence using patient surveys was performed in 8 studies<sup>(16,23,25,26,28,29,37,40)</sup>  
45 and indirect indicators such as the effect of a change in device type or the result of a guideline  
46 implementation was used in 7 studies<sup>(24,27,32,33,35,41)</sup>. The 3 RCTs<sup>(16,23,40)</sup> collected data on adherence  
47 using researcher observations and patient surveys  
48  
49  
50  
51  
52  
53  
54  
55

56  
57 Over half of the articles<sup>(23,25-32,34,35,37,38)</sup> (n=13) focused on factors affecting adherence to IPC as a  
58 primary outcome. The remaining studies<sup>(16,24,33,36,39-41)</sup> (n=7) investigated as the safety and  
59  
60

1  
2  
3 effectiveness of IPC as their main outcome. As a result of these investigations, these studies also  
4 provided data on factors affecting adherence (though this was not their aim). It is difficult to determine  
5 whether additional factors may have been uncovered from these studies (i.e. that are not reported in  
6 our findings) if the authors had specifically set out to examine how adherence to IPC could be affected.  
7  
8 Taken collectively, the patient sample sizes for each study ranged from between 67<sup>(33)</sup> to 800<sup>(32)</sup> with  
9 the majority of studies being based on over 100 patients. Articles we included were published across  
10 a 27-year period.  
11  
12  
13  
14  
15  
16  
17

## 18 **Discussion**

19  
20 This paper presents the findings of a systematic review on factors affecting adherence to IPC in the  
21 inpatient setting. In total eight factors were identified that affected adherence, with patient  
22 discomfort related to wearing the IPC device being most commonly reported and issues related to  
23 computer assisted prescribing and patients' knowledge of IPC being the least frequently reported. The  
24 majority of factors delineated (such as patient discomfort, mobilising, healthcare professional  
25 knowledge and behaviours, patient knowledge, equipment supply and demand) acted as a barrier to  
26 adherence to IPC. However, some evidence points to specific facilitators of adherence (for example  
27 the use of guidelines and protocols and computer-assisted prescribing).  
28  
29  
30  
31  
32  
33  
34

35 There are several strengths of this review. To the best of our knowledge, this is the only paper of its  
36 kind to systematically review the evidence on factors affecting adherence to IPC. Wider research  
37 within the field that has reviewed the literature relating to IPC adherence found a median adherence  
38 rate of 78%<sup>(18)</sup>. The review concluded that strategies to improve adherence are required. Our review  
39 helps to address this important gap in the evidence, shedding light on potential indicators of issue.  
40  
41  
42

43 The evidence in our review was derived from articles that provided an actual measure of adherence  
44 in clinical settings and the subsequent factors that could help to explain these adherence rates. Many  
45 of the factors relating to adherence were based on direct observation rather than self-report.  
46  
47  
48  
49

50 A caveat to mention when interpreting our findings is that while data were based on quite a large  
51 body of evidence, there were differing (and sometimes low) sample sizes as well as different aims and  
52 methodologies and countries and settings of focus. Included studies were also spread over a long  
53 period of time (twenty-seven years), in which policies and procedures around IPC may have changed.  
54  
55 Equally most of the factors affecting adherence were only reported a few times. While, admittedly  
56 this was not the primary aim of the studies included in our review, but rather was reported as  
57  
58  
59  
60

1  
2  
3 secondary finding in relation to explaining adherence rates, further work is required to understand  
4 the relative strength of the evidence. Nonetheless, this review provides a useful first step to  
5 delineating important (and perhaps otherwise empirically unknown) factors affecting adherence to  
6 IPC. These findings could be used to help inform, implement and evaluate the use of specific strategies  
7 to overcome factors causing adherence-related issues.  
8  
9  
10

11  
12  
13 There are several important implications of this work. First, discomfort with the IPC device was a  
14 considerable cause for non-adherence. The development and/or use of new or alternative IPC devices  
15 should be considered when addressing adherence issues. Research more widely in the field, that  
16 examined the use of a modern IPC device lends support for this view<sup>(42)</sup> with 86% (26/30) of patients  
17 reporting it was comfortable and that they would use it again if required. Two studies<sup>(33,40)</sup> within this  
18 review reported adherence levels when studying different machine designs and one study focused on  
19 the length of IPC sleeve<sup>(28)</sup> and its effect on adherence. There is therefore scope for further research  
20 using a randomised control study design to assess widely used IPC machines, the length of sleeves and  
21 the effect both factors have on adherence, particularly in relation to comfort.  
22  
23  
24  
25  
26  
27  
28  
29

30 Second, and related to the above point, mobility was often reported as a barrier to adherence. One  
31 likely explanation for this could be that it was uncomfortable for patient to mobilise while wearing the  
32 device, so for this reason it was removed. Evidence<sup>(24,27)</sup> from our review revealed that adherence was  
33 less of an issue for those patients that were unable to move around. However, IPC is designed to  
34 promote blood flow during immobility and if a patient is mobile, it could be concluded that IPC is no  
35 longer required and thus would not meet the criteria for data being collected as adherent or not.  
36 While this is a point that warrants further investigation, our findings suggest this could be why  
37 mobilisation (perhaps wrongly so) was identified as an adherence-related issue. Within the wider  
38 literature, a systematic review<sup>(43)</sup> on the definition used for immobility within thromboprophylaxis  
39 studies concluded that a lack of consistency in the definition of immobility may contribute to the  
40 underutilisation of thromboprophylaxis in clinical practice. In our review, the definition of mobility to  
41 the extent that IPC was no longer required was not stated by any of our included studies. In place of  
42 a widely agreed consensus, an institution-wide definition of mobility could assist individual hospitals  
43 to ensure that best practice is promoted in relation to IPC adherence.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

54  
55 Third, we found that HCP knowledge and beliefs could contribute to non-adherence. It is not clear  
56 from our studies whether on those occasions when an IPC device was not fitted, the reasons related  
57 more to the HCP not knowing they needed to do this, whether they simply forget, or whether there  
58  
59  
60

1  
2  
3 has been some other unknown issue. While this warrants further investigations, there are some  
4 relatively straightforward strategies that could be put in place, based on our preliminary findings. For  
5 example, prompts and educational leaflets could be distributed on the hospital wards to remind HCPs  
6 when the use of IPC is required and why this is important. Training is essential if optimal adherence  
7 levels are to be achieved and maintained. Equally, ensuring the layout of the ward allows easy  
8 accessibility of equipment (such as IPC) is also important, particularly, given our review revealed this  
9 to be a determinant of adherence.  
10  
11  
12  
13  
14  
15

16 Finally, our review revealed that the use of guidelines and how they are incorporated into electronic  
17 prescribing systems could act as a facilitator to adherence. Similar findings (which examined, in part  
18 the use of pre-printed orders) have been reported in a review of the barriers and facilitators to  
19 adherence to chemical thromboprophylaxis<sup>(44)</sup> within the ICU setting. Additional research that  
20 examined how electronic prescribing can lead to a reduction in errors, identified an absolute risk  
21 reduction of up to 30%<sup>(45)</sup>. Together with the evidence in this review, it could be concluded that if IPC  
22 prescribing is included in electronic prescribing systems, improvements in adherence to guidelines  
23 may be achieved.  
24  
25  
26  
27  
28  
29  
30

### 31 **Conclusion**

32 This systematic review set out to uncover the factors that affect adherence to IPC for VTE prevention  
33 in acute care. Gaining this understanding is critical in order to develop interventions, strategies and  
34 policies which are accurately targeted at meeting the challenges of improving adherence<sup>(19)</sup>. While our  
35 review has addressed an important gap in the evidence base and taken the first steps to understanding  
36 reasons why non-adherence to IPC may occur, it is clear more research is required in this area to  
37 further understand the relative strength of the evidence, so that effective strategies to overcome  
38 barriers to adherence can be sought.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

### 57 **References**

58  
59  
60



- 1  
2  
3 (1) Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Trends in the incidence  
4 of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern  
5 Med 1998;158(6):585-593.  
6
- 7  
8 (2) NHS Digital. 5.1 Deaths from venous thromboembolism (VTE) related events within 90 days post  
9 discharge from hospital. 2019; Available at: [https://digital.nhs.uk/data-and-](https://digital.nhs.uk/data-and-information/publications/clinical-indicators/nhs-outcomes-framework/current/domain-5-treating-and-caring-for-people-in-a-safe-environment-and-protecting-them-from-avoidable-harm-nof/5-1-deaths-from-venous-thromboembolism-vte-related-events-within-90-days-post-discharge-from-hospital)  
10 [information/publications/clinical-indicators/nhs-outcomes-framework/current/domain-5-treating-](https://digital.nhs.uk/data-and-information/publications/clinical-indicators/nhs-outcomes-framework/current/domain-5-treating-and-caring-for-people-in-a-safe-environment-and-protecting-them-from-avoidable-harm-nof/5-1-deaths-from-venous-thromboembolism-vte-related-events-within-90-days-post-discharge-from-hospital)  
11 [and-caring-for-people-in-a-safe-environment-and-protecting-them-from-avoidable-harm-nof/5-1-](https://digital.nhs.uk/data-and-information/publications/clinical-indicators/nhs-outcomes-framework/current/domain-5-treating-and-caring-for-people-in-a-safe-environment-and-protecting-them-from-avoidable-harm-nof/5-1-deaths-from-venous-thromboembolism-vte-related-events-within-90-days-post-discharge-from-hospital)  
12 [deaths-from-venous-thromboembolism-vte-related-events-within-90-days-post-discharge-from-](https://digital.nhs.uk/data-and-information/publications/clinical-indicators/nhs-outcomes-framework/current/domain-5-treating-and-caring-for-people-in-a-safe-environment-and-protecting-them-from-avoidable-harm-nof/5-1-deaths-from-venous-thromboembolism-vte-related-events-within-90-days-post-discharge-from-hospital)  
13 [hospital](https://digital.nhs.uk/data-and-information/publications/clinical-indicators/nhs-outcomes-framework/current/domain-5-treating-and-caring-for-people-in-a-safe-environment-and-protecting-them-from-avoidable-harm-nof/5-1-deaths-from-venous-thromboembolism-vte-related-events-within-90-days-post-discharge-from-hospital). Accessed 18/10/2019, 2019.  
14
- 15  
16 (3) Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ3. Risk factors for deep  
17 vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med  
18 2000 Mar 27;160(6):809-815.  
19
- 20  
21 (4) Heit JA, O'Fallon W, Michael Petterson TM, Lohse CM, Silverstein MD, Mohr DN, et al. Relative  
22 Impact of Risk Factors for Deep Vein Thrombosis and Pulmonary Embolism: A Population-Based  
23 Study. Arch Intern Med 2002 June 10;162(11):1245-1248.  
24
- 25  
26 (5) Jha AK, Larizgoitia I, Audera-Lopez C, Prasopa-Plaizier N, Waters H, Bates DW. The global burden  
27 of unsafe medical care: analytic modelling of observational studies. BMJ Qual Saf 2013  
28 Oct;22(10):809-815.  
29
- 30  
31 (6) All-Party Parliamentary Thrombosis Group. All-Party Parliamentary Thrombosis Group Annual  
32 Review 2017. 2017.  
33
- 34  
35 (7) Grosse SD, Nelson RE, Nyarko KA, Richardson LC, Raskob GE. The economic burden of incident  
36 venous thromboembolism in the United States: A review of estimated attributable healthcare costs.  
37 Thromb Res 2016 Jan;137:3-10.  
38
- 39  
40 (8) Noble S, Lewis R, Whithers J, Lewis S, Bennett P. Long-term psychological consequences of  
41 symptomatic pulmonary embolism: a qualitative study. BMJ Open 2014 Apr 02;4(4):e004561.  
42
- 43  
44 (9) Hunter R, Lewis S, Noble S, Rance J, Bennett PD. "Post-thrombotic panic syndrome": A thematic  
45 analysis of the experience of venous thromboembolism. British journal of health psychology  
46 2017;22(1):8-25.  
47
- 48  
49 (10) Roberts LN, Durkin M, Arya R. Annotation: Developing a national programme for VTE  
50 prevention. Br J Haematol 2017 07;178(1):162-170.  
51
- 52  
53 (11) Maynard GA. Preventing hospital-associated venous thromboembolism: a guide for effective  
54 quality improvement. : Agency for Healthcare Research and Quality, US Department of Health  
55 and ...; 2016.  
56
- 57  
58 (12) Barco S, Mahmoudpour SH, Valerio L, Klok FA, Münzel T, Middeldorp S, et al. Trends in mortality  
59 related to pulmonary embolism in the European Region, 2000–15: analysis of vital registration data  
60 from the WHO Mortality Database. The Lancet Respiratory Medicine 2019.
- 61  
62 (13) NICE. Clinical Guideline 92 Venous thromboembolism: reducing the risk: Reducing the risk of  
venous thromboembolism (deep vein thrombosis and pulmonary embolism). 2010; Available at:  
<https://www.nice.org.uk/guidance/>. Accessed 11/05/2018.

- 1  
2  
3 (14) Jacobs D.G., Piotrowski J.J., Hoppensteadt D.A., Salvator A.E., Fareed J., Browder W., et al.  
4 Hemodynamic and fibrinolytic consequences of intermittent pneumatic compression: Preliminary  
5 results. *Journal of Trauma - Injury, Infection and Critical Care* 1996 1996;40(5):710-717.  
6  
7  
8 (15) Comerota A.J., Chouhan V., Harada R.N., Sun L., Hosking J., Veermansunemi R., et al. The  
9 fibrinolytic effects of intermittent pneumatic compression mechanism of enhanced fibrinolysis. *Ann*  
10 *Surg* 1997 1997;226(3):306-314.  
11  
12 (16) Vignon P., Dequin P.F., Renault A., Mathonnet A., Paleiron N., Imbert A., et al. Intermittent  
13 pneumatic compression to prevent venous thromboembolism in patients with high risk of bleeding  
14 hospitalized in intensive care units: The CIREA1 randomized trial. *Intensive Care Med* 2013 May  
15 2013;39(5):872-880.  
16  
17 (17) Pavon JM, Adam SS, Razouki ZA, McDuffie JR, Lachiewicz PF, Kosinski AS, et al. Effectiveness of  
18 Intermittent Pneumatic Compression Devices for Venous Thromboembolism Prophylaxis in High-Risk  
19 Surgical Patients: A Systematic Review. *J Arthroplasty* 2016 Feb;31(2):524-532.  
20  
21 (18) Craigie S., Tsui J.F., Agarwal A., Sandset P.M., Guyatt G.H., Tikkinen KAO. Adherence to  
22 mechanical thromboprophylaxis after surgery: A systematic review and meta-analysis. *Thromb Res*  
23 2015 01 Oct 2015;136(4):723-726.  
24  
25 (19) WHO. Adherence to long-term therapies. Evidence for Action. World Health Organisation  
26 2003:7.  
27  
28 (20) Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the  
29 quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials* 1996;17(1):1-  
30 12.  
31  
32 (21) Wells G. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non randomised studies  
33 in meta-analyses. [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp) 2001.  
34  
35 (22) Blaxter M. Criteria for the evaluation of qualitative research papers. *Medical Sociology News*  
36 1996;22(1):68-71.  
37  
38 (23) Maxwell GL, Synan I, Hayes RP, Clarke-Pearson DL. Preference and compliance in postoperative  
39 thromboembolism prophylaxis among gynecologic oncology patients. *Obstetrics & Gynecology*  
40 2002;100(3):451-455.  
41  
42 (24) Comerota AJ, Katz ML, White JV. Why does prophylaxis with external pneumatic compression  
43 for deep vein thrombosis fail? *The American journal of surgery* 1992;164(3):265-268.  
44  
45 (25) Kim PS, Probeck K, Elitharp D, Shang T, Gasparis AP, Labropoulos N. The staff and patient  
46 perspectives on compliance with mechanical prophylaxis for venous thromboembolism. *Journal of*  
47 *Vascular Surgery: Venous and Lymphatic Disorders* 2018;6(4):441-448.  
48  
49 (26) Ritsema DF, Watson JM, Stiteler AP, Nguyen MM. Sequential compression devices in  
50 postoperative urologic patients: an observational trial and survey study on the influence of patient  
51 and hospital factors on compliance. *BMC Urol* 2013 Apr 11;13:20.  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 (27) Bockheim H.M., McAllen K.J., Baker R., Barletta JF. Mechanical prophylaxis to prevent venous  
4 thromboembolism in surgical patients: A prospective trial evaluating compliance. *J Crit Care* 2009  
5 June 2009;24(2):192-196.  
6  
7 (28) Brady D., Raingruber B., Peterson J., Varnau W., Denman J., Resuello R., et al. The use of knee-  
8 length versus thigh-length compression stockings and sequential compression devices. *Crit Care Nurs*  
9 *Q* 2007 July/September 2007;30(3):255-262.  
10  
11 (29) Cindolo L., Salzano L., Mirone V., Imbimbo C., Longo N., Kakkos S.K., et al. Thromboprophylaxis  
12 in radical retropubic prostatectomy: Efficacy and patient compliance of a dual modality. *Urol Int*  
13 2009 July 2009;83(1):12-18.  
14  
15 (30) Elpern E, Killeen K, Patel G, Senecal PA. The application of intermittent pneumatic compression  
16 devices for thromboprophylaxis: AN observational study found frequent errors in the application of  
17 these mechanical devices in ICUs. *Am J Nurs* 2013 quiz 37; Apr;113(4):30-36.  
18  
19 (31) Gardiner DA, Kelly B. Improving rates of intermittent pneumatic compression therapy  
20 utilization. *Hosp Pract (Minneap)* 2013 Aug;41(3):40; Aug-47.  
21  
22 (32) Novis SJ, Havelka GE, Ostrowski D, Levin B, Blum-Eisa L, Prystowsky JB, et al. Prevention of  
23 thromboembolic events in surgical patients through the creation and implementation of a  
24 computerized risk assessment program. *J Vasc Surg* 2010 Mar;51(3):648-654.  
25  
26 (33) Obi A.T., Alvarez R., Reames B.N., Moote M.J., Thompson M.A., Wakefield T.W., et al. A  
27 prospective evaluation of standard versus battery-powered sequential compression devices in  
28 postsurgical patients. *Am J Surg* 2015 01 Apr 2015;209(4):675-681.  
29  
30 (34) Palmerola K.L., Brock C.O., D'Alton M.E., Friedman AM. Compliance with mechanical venous  
31 thromboprophylaxis after cesarean delivery. *Journal of Maternal-Fetal and Neonatal*  
32 *Medicine* 2016 01 Oct 2016;29(19):3072-3075.  
33  
34 (35) Chen M, Sarnoski KA, Jacques LH, Klatt T, Palatnik A. Sequential compression device compliance  
35 in pregnant women requiring antepartum admission. *The Journal of Maternal-Fetal & Neonatal*  
36 *Medicine* 2019:1-7.  
37  
38 (36) Cornwell EE3, Chang D, Velmahos G, Jindal A, Baker D, Phillips J, et al. Compliance with  
39 sequential compression device prophylaxis in at-risk trauma patients: a prospective analysis. *Am*  
40 *Surg* 2002 May;68(5):470-473.  
41  
42 (37) Brady MA, Carroll AW, Cheang KI, Straight C, Chelmow D. Sequential compression device  
43 compliance in postoperative obstetrics and gynecology patients. *Obstet Gynecol* 2015 Jan;125(1):19-  
44 25.  
45  
46 (38) GarciaOlivares P., Guerrero J.E., Keough E., Galdos P., Carriedo D., Murillo F., et al. Clinical  
47 factors associated with inappropriate prophylaxis of venous thromboembolic disease in critically ill  
48 patients. A single day cross-sectional study. *Thromb Res* 2016 01 Jul 2016;143:111-117.  
49  
50 (39) Yamamoto T., Nakamura M., Kuroiwa M., Tanaka K. Current prevention practice for venous  
51 thromboembolism in Japanese intensive care units. *Journal of Anesthesia* 2013 December  
52 2013;27(6):931-934.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 (40) Sobieraj-Teague M, Hirsh J, Yip G, Gastaldo F, Stokes T, Sloane D, et al. Randomized controlled  
4 trial of a new portable calf compression device (Venowave) for prevention of venous thrombosis in  
5 high-risk neurosurgical patients. *J Thromb Haemost* 2012 Feb;10(2):229-235.  
6

7  
8 (41) Maffei F.H.A., Sato A.C., Filho F.T., da Silva S.C., Atallah A. Effect of the implementation of a  
9 guideline for venous thromboembolism prophylaxis in surgical patients. *Rev Assoc Med Bras* 2009  
10 2009;55(5):587-592.  
11

12 (42) Guimicheva B, Patel JP, Roberts LN, Subramanian D, Arya R. Women's views, adherence and  
13 experience with postnatal thromboprophylaxis. *Thromb Res* 2019;173:85-90.  
14

15 (43) Emed JD, Morrison DR, Des Rosiers L, Kahn SR. Definition of immobility in studies of  
16 thromboprophylaxis in hospitalized medical patients: a systematic review. *Journal of Vascular*  
17 *Nursing* 2010;28(2):54-66.  
18

19 (44) Cook D, Duffett M, Lauzier F, Ye C, Dodek P, Paunovic B, et al. Barriers and facilitators of  
20 thromboprophylaxis for medical-surgical intensive care unit patients: a multicenter survey. *J Crit*  
21 *Care* 2014;29(3):471. e1-471. e9.  
22  
23

24 (45) Dalton K, O'Brien G, O'Mahony D, Byrne S. Computerised interventions designed to reduce  
25 potentially inappropriate prescribing in hospitalised older adults: a systematic review and meta-  
26 analysis. *Age Ageing* 2018;47(5):670-678.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1: Characteristics of included studies**

Author	Study design	Setting	Studies main objective	Focus was adherence barriers / facilitators?	Sample size	Participants (mean age)	Country
Bockheim 2009 (27)	Prospective observational	Critical care & Ward care	Comparison of IPC compliance between ICU and non ICU areas	Yes	150	Female 73, Male 77 (62)	USA
Brady 2007 (28)	Prospective observational	Acute nursing care wards	To assess comfort and fit and compliance of knee vs thigh length IPC	Yes	137	Female 72, Male 65 (55)	USA
Brady 2015 (37)	Prospective observational	Caesarean or gynaecological surgery	To assess impact of education on compliance to IPC	Yes	228	Female 59 (38)	USA
Chen 2019 (35)	Prospective observational	Obstetrics	Assess the effectiveness of an intervention in improving compliance to IPC	Yes	76	Female 76 (28)	USA
Cindolo 2009 (29)	Prospective observational	Radical retropubic prostatectomy surgery	To assess acceptability and satisfaction to IPC	Yes	184	Male 184 (69)	USA
Comerota 1992 (24)	Prospective observational	Critical care & Ward care	Comparison of IPC compliance between ICU and non ICU areas	No	138	Not reported	USA
Cornwell 2002 (36)	Prospective observational	Surgical trauma	To assess compliance of IPC in trauma patients	No	227	Female 39, Male 188 (37)	USA
Elphern 2013 (30)	Prospective observational	Critical care	Identifying reasons for errors in the application of IPC	Yes	123	Female 42, Male 54	USA
García-Olivares 2016 (38)	Prospective observational	Critical care	Factors associated with inadequate thromboprophylaxis in critically ill patients	Yes	777	Female 270, Male 507 (61)	Spain
Gardiner 2013 (31)	Prospective observational	Surgical wards	Quality improvement to increase IPC compliance	Yes	339	Not reported	USA
Kim 2018 (25)	Cohort Study	Surgical, medical & critical care	Accuracy of VTE assessment, compliance to IPC and effect of education on compliance	Yes	200	Female 97, Male 103 (62)	USA
Maffei 2009 (41)	Retrospective observational	Surgical wards	Before and after study of implementation of thromboprophylaxis guidelines	No	150	Female 77, Male 73 (64)	Brazil
Maxwell 2002 (23)	Randomised controlled trial	Surgical gynaecology	To assess preference and compliance in patients receiving heparin and IPC	Yes	104	Female 104 (61)	USA
Novis 2009 (32)	Prospective observational	Surgical wards	Utilisation of DVT prophylaxis after implementation of electronic risk assessment	Yes	800	Female 15, Male 785 (64)	USA
Obi 2015 (33)	Prospective observational	Surgical wards	Comparison of compliance with a standard vs battery powered IPC device	No	67	Female 32, Male 35 (51)	USA

Palmerola 2015 (34)	Prospective observational	Obstetrics	Compliance with IPC after caesarean delivery	Yes	293	Female 293 (32)	USA
Ritsema 2013 (26)	Observational	Surgical wards	Study of the influence of hospital and patient factors on compliance	Yes	100	Female 24, Male 76	USA
Sobierag- Teague 2012 (40)	Randomised controlled trial	Neurosurgery	Trialling the efficacy and tolerability of an IPC device	No	75	Female 31, Male 44 (62)	Canada
Vignon 2013 (16)	Randomised controlled trial	Critical care	Effectiveness of compression stockings with and without IPC	No	205	Female 72, Male 132 (55)	France
Yamamoto 2013 (39)	Prospective observational	Critical care	Exploring the current practice of VTE prevention in Japanese ICUs	No	470	Female 168, Male 302 (65)	Japan

**Table 2: Factors affecting adherence**

Author	Factors	Findings
Bockheim 2009 (27)	Intensive care context	ICU has greater compliance than non-ICU
Brady 2007 (28)	Patient discomfort	Cause of non-adherence was; 39% discomfort
	Mobilisation	46% had just ambulated
	Healthcare professional knowledge and behaviours	13% the nurse had not reapplied the IPC after transfer from another unit
Brady 2015 (37)	Healthcare professional knowledge and behaviours	When asked, 23% of patients said nurses instruction to not wear
	Equipment supply and demand	13% did not have part of the device in the room
	Mobilisation	17% said they had just returned to bed, 16% walking around, 7% just about to walk around
Chen 2019 (35)	Patient discomfort	15% of patients said the IPC was uncomfortable
	Computer assisted prescribing	A pre-checked electronic order increased prescribing adherence from 46% to 77%
Cindolo 2009 (29)	Computer assisted prescribing	Noise and insomnia were reported as being a negative experience in 23% and 44% of cases respectively. Authors state these issues were reasons why 3% had IPC removed early
Comerota 1992 (24)	Patient discomfort	ICU has greater compliance than non-ICU
Cornwell 2002 (36)	Intensive care context	ICU has greater compliance than non-ICU
Elphern 2013 (30)	Healthcare professional knowledge and behaviours	Compliance rate of 53%. Information reported about non-compliance was that the device was not in place (95%)
	Healthcare professional knowledge and behaviours	In 51% of non-adherence observed, IPC sleeves were not correctly applied and 24% the machine was not switched on
García-Olivares 2016 (38)	Mobilisation	Patients with invasive mechanical ventilation and complete bedrest had greater compliance
	Guidelines	use of a protocol and risk scoring system led to decreased risk of inappropriate VTE prophylaxis
Gardiner 2013 (31)	Equipment supply and demand	In 38% of non-adherent cases the IPC machine was not in the room, locating IPC machines in rooms resulted in adherence from 26% to 44%
	Healthcare professional knowledge and behaviours	A nursing knowledge and beliefs survey yields information about barriers that nurses bring to the use of IPC
Kim 2018 (25)	Knowledge	40% overall non-adherence to IPC. Of these, 40% said that no one informed them they needed to keep IPC on
	Patient discomfort	40% overall non-adherence to IPC, 33% said this was due to discomfort
Maffei 2009 (41)	Equipment supply and demand	After guidelines were introduced, IPC prescription increased from 26% to 32%
Maxwell 2002 (23)	Guidelines	After guidelines were introduced, IPC prescription increased from 26% to 32%
Novis 2009 (32)	Healthcare professional knowledge and behaviours	Of 736 observations, non-compliance was noted in 2.7% of cases and this was related to the machine not being switched on
	Computer assisted prescribing	Electronic suggestion of thromboprophylaxis increased the use of IPC from 50% to 63%
Obi 2015 (33)	Device related	A battery powered device facilitated adherence through enabling mobilisation
	Patient discomfort	A new machine design led to fewer reports of patient discomfort (33% vs 13%)
	Mobilisation	Problems with mobilisation were less using a new machine (71% vs 29%)
Palmerola 2015 (34)	Mobilisation	38% of patients classed as non-adherent to IPC therapy had it discontinued due to liberal standards for ambulation
Ritsema 2013 (26)	Mobilisation	Not replaced after mobilising accounted for 50% of non-compliant observations
	Equipment supply and demand	Lack of machine or cuffs accounted for 22% of non-adherence
	Patient discomfort	Patient discomfort accounted for 19% of non-adherence
Sobierag-Teague 2012 (40)	Patient discomfort	48% of users discontinued the device at night. Comfort related issues discussed but not explicitly linked to non-adherence

1			
2			
3	Vignon 2013		
4	(16)	Patient discomfort	7% non-compliance in the AES + IPC group. IPC was discontinued due to discomfort, noise and restlessness
5	Yamamoto		
6	2013 (39)	Guidelines	Combined AES and IPC mechanical prophylaxis was higher in units with a protocol than without (88% vs 80%)
7			
8			
9			
10			
11			
12			
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			
26			
27			
28			
29			
30			
31			
32			
33			
34			
35			
36			
37			
38			
39			
40			
41			
42			
43			
44			
45			
46			
47			
48			
49			
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
60			

For peer review only



Figure 1: PRISMA flow chart of search results retrieved 30<sup>th</sup> May 2019




Figure 1

169x156mm (120 x 120 DPI)

## Search strategy

Population	Intervention	Comparison	Outcomes
Intermittent pneumatic compression OR Sequential compression	Interven\$ OR Strateg\$ OR Guideline\$ OR Educat\$ OR Inform\$ OR PDSA OR Plan do study act OR Improv\$ OR Implement\$ OR Toleran\$ OR Aware\$ OR Present\$ OR Program\$ OR Plan\$ OR Approach\$ OR Project\$ OR Procedure\$ OR Polic\$ OR Method\$ OR Design\$ OR Action\$ OR Part\$ OR Involv\$ OR Practice\$ OR Process\$ OR System\$ OR Technique\$ OR Scheme\$	N/A	Complian\$ OR Adhere\$ OR Efficacy OR Effective\$ OR Outcome\$ OR Success\$ OR Fail\$ OR Fidelity

# Reporting checklist for systematic review and meta-analysis.

Based on the PRISMA guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA reporting guidelines, and cite them as:

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

	Reporting Item	Page Number
<b>Title</b>		
	<a href="#">#1</a> Identify the report as a systematic review, meta-analysis, or both.	1

## Abstract

1	Structured	<a href="#">#2</a>	Provide a structured summary including, as applicable:	2
2				
3	summary		background; objectives; data sources; study eligibility criteria,	
4			participants, and interventions; study appraisal and synthesis	
5			methods; results; limitations; conclusions and implications of	
6			key findings; systematic review registration number	
7				
8				
9				
10				
11				
12				
13	<b>Introduction</b>			
14				
15				
16	Rationale	<a href="#">#3</a>	Describe the rationale for the review in the context of what is	3
17			already known.	
18				
19				
20				
21				
22	Objectives	<a href="#">#4</a>	Provide an explicit statement of questions being addressed	4
23			with reference to participants, interventions, comparisons,	
24			outcomes, and study design (PICOS).	
25				
26				
27				
28				
29	<b>Methods</b>			
30				
31				
32	Protocol and	<a href="#">#5</a>	Indicate if a review protocol exists, if and where it can be	4
33	registration		accessed (e.g., Web address) and, if available, provide	
34			registration information including the registration number.	
35				
36				
37				
38				
39				
40	Eligibility criteria	<a href="#">#6</a>	Specify study characteristics (e.g., PICOS, length of follow-up)	4
41			and report characteristics (e.g., years considered, language,	
42			publication status) used as criteria for eligibility, giving rational	
43				
44				
45				
46				
47				
48	Information	<a href="#">#7</a>	Describe all information sources in the search (e.g., databases	4
49	sources		with dates of coverage, contact with study authors to identify	
50			additional studies) and date last searched.	
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1	Search	<a href="#">#8</a>	Present full electronic search strategy for at least one	5
2				
3			database, including any limits used, such that it could be	
4				
5			repeated.	
6				
7				
8	Study selection	<a href="#">#9</a>	State the process for selecting studies (i.e., for screening, for	5
9				
10			determining eligibility, for inclusion in the systematic review,	
11				
12			and, if applicable, for inclusion in the meta-analysis).	
13				
14				
15				
16	Data collection	<a href="#">#10</a>	Describe the method of data extraction from reports (e.g.,	5
17				
18	process		piloted forms, independently by two reviewers) and any	
19				
20			processes for obtaining and confirming data from investigators.	
21				
22				
23				
24	Data items	<a href="#">#11</a>	List and define all variables for which data were sought (e.g.,	Supp.
25				
26			PICOS, funding sources), and any assumptions and	file
27				
28			simplifications made.	
29				
30				
31	Risk of bias in	<a href="#">#12</a>	Describe methods used for assessing risk of bias in individual	5
32				
33	individual studies		studies (including specification of whether this was done at the	
34				
35			study or outcome level, or both), and how this information is to	
36				
37			be used in any data synthesis.	
38				
39				
40				
41	Summary	<a href="#">#13</a>	State the principal summary measures (e.g., risk ratio,	n/a
42				
43	measures		difference in means).	
44				
45				
46				
47	Planned	<a href="#">#14</a>	Describe the methods of handling data and combining results	n/a
48				
49	methods of		of studies, if done, including measures of consistency (e.g., I <sup>2</sup> )	
50				
51	analysis		for each meta-analysis.	
52				
53				
54				
55				
56				
57				
58				
59				
60				

1	Risk of bias	<a href="#">#15</a>	Specify any assessment of risk of bias that may affect the	n/a
2				
3	across studies		cumulative evidence (e.g., publication bias, selective reporting	
4			within studies).	
5				
6				
7				
8				
9	Additional	<a href="#">#16</a>	Describe methods of additional analyses (e.g., sensitivity or	n/a
10				
11	analyses		subgroup analyses, meta-regression), if done, indicating which	
12			were pre-specified.	
13				
14				
15				
16	<b>Results</b>			
17				
18				
19	Study selection	<a href="#">#17</a>	Give numbers of studies screened, assessed for eligibility, and	5
20			included in the review, with reasons for exclusions at each	
21			stage, ideally with a <a href="#">flow diagram</a> .	
22				
23				
24				
25				
26				
27	Study	<a href="#">#18</a>	For each study, present characteristics for which data were	6
28				
29	characteristics		extracted (e.g., study size, PICOS, follow-up period) and	
30			provide the citation.	
31				
32				
33				
34				
35	Risk of bias	<a href="#">#19</a>	Present data on risk of bias of each study and, if available, any	n/a
36				
37	within studies		outcome-level assessment (see Item 12).	
38				
39				
40	Results of	<a href="#">#20</a>	For all outcomes considered (benefits and harms), present, for	n/a
41				
42	individual studies		each study: (a) simple summary data for each intervention	
43			group and (b) effect estimates and confidence intervals, ideally	
44			with a forest plot.	
45				
46				
47				
48				
49				
50	Synthesis of	<a href="#">#21</a>	Present the main results of the review. If meta-analyses are	7
51				
52	results		done, include for each, confidence intervals and measures of	
53			consistency.	
54				
55				
56				
57				
58				
59				
60				

1	Risk of bias	<a href="#">#22</a>	Present results of any assessment of risk of bias across	n/a
2				
3	across studies		studies (see Item 15).	
4				
5				
6	Additional	<a href="#">#23</a>	Give results of additional analyses, if done (e.g., sensitivity or	n/a
7				
8	analysis		subgroup analyses, meta-regression [see Item 16]).	
9				
10				
11				
12	<b>Discussion</b>			
13				
14				
15	Summary of	<a href="#">#24</a>	Summarize the main findings, including the strength of	10
16				
17	Evidence		evidence for each main outcome; consider their relevance to	
18				
19			key groups (e.g., health care providers, users, and policy	
20				
21			makers	
22				
23				
24				
25	Limitations	<a href="#">#25</a>	Discuss limitations at study and outcome level (e.g., risk of	10
26				
27			bias), and at review level (e.g., incomplete retrieval of identified	
28				
29			research, reporting bias).	
30				
31				
32	Conclusions	<a href="#">#26</a>	Provide a general interpretation of the results in the context of	10
33				
34			other evidence, and implications for future research.	
35				
36				
37				
38	<b>Funding</b>			
39				
40				
41	Funding	<a href="#">#27</a>	Describe sources of funding or other support (e.g., supply of	1
42				
43			data) for the systematic review; role of funders for the	
44				
45			systematic review.	
46				
47				
48				

None The PRISMA checklist is distributed under the terms of the Creative Commons Attribution License CC-BY. This checklist can be completed online using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

# BMJ Open

## Intermittent pneumatic compression for venous thromboembolism prevention: a systematic review on factors affecting adherence

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-037036.R1
Article Type:	Original research
Date Submitted by the Author:	15-Jun-2020
Complete List of Authors:	Greenall, Richard; King's College Hospital NHS Foundation Trust, Executive Offices, Princess Royal University Hospital, Farnborough, BR6 8ND Davis, Rachel; King's College London, Centre for Implementation Science , Health Services and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience
<b>Primary Subject Heading</b>:	Haematology (incl blood transfusion)
Secondary Subject Heading:	Intensive care, Nursing
Keywords:	Thromboembolism < CARDIOLOGY, Bleeding disorders & coagulopathies < HAEMATOLOGY, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Intermittent pneumatic compression for venous thromboembolism prevention: a**  
4 **systematic review on factors affecting adherence**  
5  
6  
7

8 **Authors**  
9

10 Richard Greenall, BSc, MSc<sup>1</sup>

11 Rachel Davis, BSc, MSc, PhD<sup>2</sup>  
12

13 <sup>1</sup>King's College Hospital NHS Foundation Trust

14 Executive Offices

15 Princess Royal University Hospital

16 Farnborough

17 BR6 8ND

18 Email: writetorichg@gmail.com  
19

20  
21 Centre for Implementation Science

22 <sup>2</sup>Health Services and Population Research Department,

23 Institute of Psychiatry, Psychology and Neuroscience

24 King's College London

25 2nd Floor, Room E2.19

26 16 De Crespigny Park

27 Denmark Hill

28 LONDON

29 SE5 8AF

30 Email: [rachel.davis@kcl.ac.uk](mailto:rachel.davis@kcl.ac.uk)  
31

32  
33  
34 Corresponding author: Richard Greenall  
35  
36

37 **Competing interests**

38 None declared  
39

40 **Contributorship statement**

41 RG and RD designed the paper and were responsible for its conceptualisation. RG drafted the paper  
42 and RD edited it. Both authors were involved in the screening of the articles included in the review  
43 and have read and approved the final version of the manuscript.  
44

45 **Funding**

46 No funder  
47

48 **Data sharing statement**

49 All data generated or analysed during this study are included in this published article (and its  
50 supplementary information files).  
51

52 **Word count;** 4713  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Objective** Venous thromboembolism (VTE) is a potentially fatal complication of hospitalisation. Intermittent pneumatic compression (IPC) is one approach to reducing the likelihood of a VTE. Adherence to IPC is known to be inadequate though the reasons for this remain unclear. This systematic review explores factors that affect adherence to IPC in the inpatient context.

**Methods** – information sources -EMBASE, MEDLINE and PsycINFO were searched for literature between January 1960 to May 2019. Eligibility criteria - studies were included if they focused on inpatient care and examined factors affecting adherence to IPC devices.

**Results** – included studies - a total of 20 out of 1476 studies were included. Synthesis of results - Eight factors were identified that affected adherence: patient discomfort (n=8), healthcare professionals' knowledge and behaviours (n=6), mobilisation (n=6), equipment supply and demand (n=3), the use of guidelines (n=3), intensive care context (n=2), computer-assisted prescribing (n=2) and patients' knowledge of IPC (n=1).

**Conclusion** Overall while the evidence base is quite limited, a number of factors were shown to affect adherence to IPC. These findings could be used to inform future research and quality improvement efforts to increase adherence in this very important, but currently under-researched area.

**Keywords;** Intermittent pneumatic compression, adherence, compliance, thromboprophylaxis, venous thromboembolism, VTE, deep vein thrombosis, pulmonary embolism

### Strengths

- First known review of the evidence affecting adherence to IPC
- Eight factors were identified that resulted in measurable changes to adherence to IPC

### Limitations

- Results largely based on direct observation rather than self-report
- Studies generally had low sample sizes
- Studies with different aims and methodologies were included.

## Background

Venous thromboembolism (VTE) is a term that most commonly refers to deep vein thrombosis (DVT) and pulmonary embolism (PE). VTE affects one in 1000 people annually<sup>(1)</sup> and in England in 2018 VTE was recorded as a cause of death in 12,000 cases<sup>(2)</sup>. Compared to baseline risk, hospitalisation has been correlated with an 8-fold increased risk of VTE in medical admissions and a 21-fold increased risk in surgical admissions<sup>(3)</sup> with one study estimating that up to 50% of 625 cases of VTE in the community were related to hospitalisation<sup>(4)</sup>. Secondary to adverse drug events, VTE is the leading complication of hospitalisation worldwide<sup>(5)</sup>.

The financial cost of hospital associated VTE is high. In 2017, a UK survey revealed the average cost of treating VTE was £938,357 for each local NHS region<sup>(6)</sup>. At a patient level, a review<sup>(7)</sup> identified an increase in cost of \$14,000 for initial diagnosis and the first year of treatment for those with VTE compared with non-VTE affected patients. VTE can have a significant impact on a person's psychosocial well-being with research to suggest that it can be a traumatic, life-changing event which can lead to post traumatic stress disorder<sup>(8,9)</sup>.

Since hospitalisation increases the risk of VTE, it is important to consider if anything can be done to reduce the risk within this context. In England, the national VTE prevention programme combined a mandate for assessment of patient's risk on admission to hospital with best practice prevention guidelines. Early results indicate that its efforts have led to reduced morbidity and mortality<sup>(10)</sup>. Similar efforts have been made in the USA<sup>(11)</sup> and throughout Europe, recent evidence indicates that better management of the risk of VTE has reduced VTE related mortality from 12.8 to 6.5 deaths per hundred thousand<sup>(12)</sup>.

Risk assessing all patients on admission to hospital leads to identification of patients at high risk who need thromboprophylaxis (i.e. treatments to prevent VTE). In the UK, national guidelines<sup>(13)</sup> advise using the chemical thromboprophylaxis low molecular weight heparin for most groups of at-risk hospitalised patients. Mechanical thromboprophylaxis is advised for most surgical patients and other high-risk groups, such as patients with stroke. Graduated compression stockings (GCS) are one type of mechanical intervention. GCS exerts graded pressure around the legs, increasing the speed of blood flow and reducing the opportunity for VTE to form<sup>(14)</sup>.

1  
2  
3 Intermittent pneumatic compression (IPC) is another type of mechanical device. Fabric sleeves that  
4 wrap around a patient's legs are attached to a pump using a tube and are periodically inflated and  
5 deflated. IPC is thought to reduce VTE by increasing the speed of blood flow and reducing  
6 hypercoagulability through the IPC action stimulating the vessel walls fibrinolytic activity<sup>(15,16)</sup>.  
7  
8 Evidence demonstrates that combining IPC and GCS decreases the incidence of VTE to a greater effect  
9 than either separately<sup>(17)</sup>. Systematic reviews found the same increased effect when combining IPC  
10 and pharmacological prophylaxis<sup>(18)</sup> and that IPC can reduce the incidence of VTE in surgical  
11 patients<sup>(19)</sup>. However, despite these benefits, research has shown considerable variability in  
12 adherence to IPC device use, with a systematic review of seven studies in acute hospitals reporting a  
13 median adherence rate of 78% (range 40%-89%)<sup>(20)</sup>. The authors concluded that strategies to improve  
14 adherence are needed but the question remains as to why non-adherence occurs.  
15  
16  
17  
18  
19  
20  
21  
22

23 While factors affecting adherence have been reviewed within surgical specialities<sup>(19)</sup>, to the best of our  
24 knowledge, no attempt has been made to comprehensively investigate the factors that could facilitate  
25 or impede adherence to IPC across all specialities. This paper aims to address this important gap in  
26 the evidence base by systematically reviewing the factors that influence adherence to IPC for VTE  
27 prevention in acute care. Gaining this understanding is critical in order to develop interventions,  
28 strategies and policies that are accurately targeted at meeting the challenges of improving  
29 adherence<sup>(21)</sup>.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

## 40 **Methods**

### 41 *Patient and public involvement*

42 No patient was involved.  
43  
44

### 45 *Search strategy*

46 EMBASE, MEDLINE and PsycINFO were searched for relevant literature published between January  
47 1960 to May 2019. The search strategy comprised terms relating to: 1) population (e.g. 'IPC'); 2)  
48 Intervention (e.g. 'strategies') and; 3) outcomes (e.g. 'adherence'). The search was customized to each  
49 database and restricted to titles and abstracts to tighten its specificity. A sensitivity analysis was  
50 performed to ensure the search results included key articles identified through an initial scoping  
51 review. Forward and backward citation searching and hand searching of key journals were performed  
52 to minimize the likelihood of missing relevant papers. The final search was conducted on 30th May  
53 2019 (for the full search strategy please refer to Supplementary file 1).  
54  
55  
56  
57  
58  
59  
60

### *Inclusion criteria*

Based on UK national guidelines that were current at the time of this review's development (January 2018)<sup>(13)</sup>, the definition of IPC in this review includes only devices that are applied to the legs and excludes foot compression devices. The first stage of screening (title and abstract) was intentionally inclusive and retained any empirical articles that mentioned adherence to IPC in any context. In the second stage (full text), tighter restrictions applied. Articles were included if they reported barriers or facilitators to adherence to IPC in the inpatient context and included a measure of the effect (percentage change in adherence to IPC) of such factors on adherence (either as a primary or secondary aim or an indirect finding in the results). Dissertations and doctoral theses, books, book reviews, conference posters and presentations, editorials and commentaries were excluded, as were articles not published in English or those focused on patients under 18 years of age. Review/commentary papers that addressed adherence to IPC<sup>(20)</sup> were examined for relevant empirical papers but the reviews themselves were excluded.

### *Study selection and data extraction*

Articles were screened for relevance by the lead author (RG). The second author (RD) screened 20% of the articles at abstract stage and 100% at full-text stage. Discrepancies were resolved through joint discussion between the authors. Dual data extraction of the included articles was conducted independently by both authors and then checked for consistency. We did not predetermine the factors that could affect adherence to IPC. Rather, we reviewed the data in each article and then grouped these into categories of factors that could affect adherence to IPC. These factors were decided initially by the first author (RG) and then checked by the second author (RD). Disagreements were resolved by joint discussion until consensus was reached.

### *Quality Assessment*

While numerous scales are available to assess the methodological quality of studies, these are often restricted to specific study designs, including randomised controlled trials<sup>(22)</sup>; case-control and cohort studies<sup>(23)</sup>; and qualitative studies<sup>(24)</sup>. Given our review included articles that employed heterogeneous study designs and differing aims, we did not use a quality assessment scale, nor did we deem this meaningful. We did however consider differences in the methodologies that could potentially bias the findings to enable greater understanding of the relative strengths and weaknesses of the research. To gain a comprehensive understanding of the full body of evidence, we did not exclude articles based on their methodological quality.

## Results

### *Study selection*

Of 1476 articles retrieved, 1324 were excluded at the first stage of screening (title/abstract) and 132 (out of the remaining 152) were excluded after full-text screening, resulting in 20 articles. Two of the included articles were added through handsearching<sup>(25,26)</sup> (see Figure 1). Upon examination, these studies were missed in the initial search due to the use of the word 'external' instead of 'intermittent' to describe pneumatic compression. Further scoping the literature (using the term 'external') revealed there were no other additional articles that needed to be included.

Insert Figure 1 here

### *Characteristics of included studies*

Articles were published between 1992 and 2018 across six countries, including the USA (n= 15<sup>(25-39)</sup>), Spain (n= 1<sup>(40)</sup>), Japan (n=1<sup>(41)</sup>), Canada (n=1<sup>(42)</sup>), France (n=1<sup>(17)</sup>) and Brazil (n=1<sup>(43)</sup>). Characteristics of patients and care locations included critical care<sup>(17,26,29,40,41)</sup>, general surgical wards<sup>(28,33-35,38,42,43)</sup> and gynaecology<sup>(25,36,37,39)</sup> specialties. Factors affecting adherence to IPC was the primary focus of 13 studies<sup>(25,27-34,36,37,39,40)</sup>. A further seven studies<sup>(17,26,35,38,41-43)</sup> focused on IPC device safety and effectiveness in preventing VTE but also reported barriers or facilitators to IPC adherence. Seventeen of the studies were observational<sup>(26-41,43)</sup>, using surveys and clinical observations as investigation tools. The remaining three studies were RCTs<sup>(17,25,42)</sup>. Due to wide heterogeneity in study methodologies, meta-analysis was not possible. Table 1 details the characteristics of the included studies.

Insert table 1 here

### **Factors affecting adherence to IPC**

Articles varied considerably in the level of content and detail provided regarding study designs and adherence to IPC. We report the main findings here and provide a more detailed analysis of findings for studies where this was possible. Table 2 outlines the eight factors that were identified that affected adherence to IPC.

Insert table 2 here

#### *1. Patient discomfort*

1  
2  
3 Patient discomfort associated with wearing the IPC device was identified in eight  
4 studies<sup>(17,27,28,30,31,35,39,42)</sup>. Vignon<sup>(17)</sup> identified poor adherence in 7% (14/204) of patients due to  
5 discomfort, noise and restlessness. Brady<sup>(30)</sup> observed the effect of the length of the IPC sleeve on  
6 comfort and subsequent non-adherence. Overall adherence was 29% (40/137) based on a one-off  
7 observation. Eighty-five percent of non-adherent users had been wearing thigh length (53%) or knee  
8 length (32%) sleeves. Discomfort was reported as a reason for non-adherence by 39% (58/149) of  
9 patients who were non-adherent. Those wearing thigh length sleeves reported double the number of  
10 complaints compared to those wearing knee length sleeves (39 vs 15).

11  
12 Brady<sup>(39)</sup> examined adherence over several days post-operatively. Taking multiple observations of the  
13 same patients, adherence was 75% (43/57) on day zero, 53% (148/278) on day 2, and 44% (11/25) on  
14 day 4. Patients who were non-adherent were asked why at the time of observation and 15% (53/362  
15 responses) stated discomfort as a reason. Kim<sup>(27)</sup> compared two groups of 100 patients in a  
16 multifaceted improvement strategy to increase adherence to IPC. Post intervention a slight  
17 improvement was achieved (24% versus 26%). Ninety-two percent of nurses (58/63) and 29% (4/14)  
18 of non-adherent patients reported discomfort as a reason for the lack of adherence.

19  
20 Ritsema<sup>(28)</sup> found that patients were non-adherent 21% of the time (98/457 observations) with patient  
21 interviews indicating that discomfort was a reason in 19% (19/100) of responses. Sobieraj-Teague<sup>(42)</sup>  
22 trialled the efficacy of a newly developed IPC machine which allowed the patient to mobilise  
23 independently of a power cable through the utilisation of batteries and small product design. Poor  
24 adherence was found in 49% of users (35/72), in particular at night, with patients reported they  
25 discontinued therapy due to insomnia. Similar findings, but to a much lesser extent were reported by  
26 Cindolo<sup>(31)</sup> when evaluating the comfort and tolerability of a specific IPC device. While non-adherence  
27 was only 3% (6/184), patients who requested discontinuation of IPC therapy did so due to noise and  
28 insomnia.

29  
30 A final study by Obi<sup>(35)</sup> was designed as a retrospective review examining whether a different design  
31 of IPC device would reduce non-adherence. Comparing a standard machine to a new machine,  
32 adherence to the standard machine was 47% versus 85% for the newer machine. Of responses from  
33 those patients wearing the standard compared to the new machine (21 and 24 respectively), problems  
34 with discomfort as reported less (33% vs. 13%).

## 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

### 2. Healthcare professional knowledge and behaviours

Failure of healthcare professionals to apply or provide IPC when prescribed was identified in six  
studies<sup>(25,30,32,33,38,39)</sup>. Brady<sup>(30)</sup> found that 16% (12/73) of survey respondents reported that the nurse



1  
2  
3 had never initiated IPC therapy or had not replaced the sleeves after transfer of the patient from  
4 another location. Brady<sup>(39)</sup> found that 23% (82/356) of non-adherent patients stated the nurse had  
5 informed them that they did not require IPC anymore.  
6  
7

8 Cornwell<sup>(38)</sup> observed adherence of 53% (out of 712/1343 observations of 233 patients). The authors  
9 reported that this was because the device was 'not in place'. The time of day that non-adherence was  
10 most frequently noted was in the early afternoon and the authors concluded that it is both HCPs and  
11 patients who need to be educated about the importance of wearing IPC as the patient may have been  
12 the one who removed it.  
13  
14

15 Elphern<sup>(32)</sup> reported that errors in the application of IPC therapy were identified in 49% (477/966) of  
16 observations of a cohort of 123 patients. In 244 observations the sleeves were incorrectly applied to  
17 the patient and in 116 observations the pump was not turned on. Similar findings by Maxwell<sup>(25)</sup> in 104  
18 patients identified that the reason for non-adherence in 3% (20/736) of observations was that the IPC  
19 was not turned on. Gardiner<sup>(33)</sup> reported that only 26% (89/339) of patients were adherent to IPC on  
20 initial audit. A survey of nursing beliefs, practice and knowledge determined that part of the problem  
21 was deficiencies in nursing knowledge. Education interventions as well as placing IPC machines in  
22 individual rooms of patients improved adherence from 26% to 44%.  
23  
24  
25  
26  
27  
28  
29  
30

### 31 *3. Mobilisation*

32 Issues relating to mobilisation were identified as factors affecting adherence in six studies<sup>(28,30,35,36,39,40)</sup>.  
33 Brady<sup>(30)</sup>, found that of 149 responses from non-adherent patients, 46% (68/149) of patients reported  
34 that they had just mobilised. Similarly, Brady<sup>(39)</sup> found that 16% (59/362) of patients reported that  
35 they had just mobilised. Similarly, Brady<sup>(39)</sup> found that 16% (59/362) of patients reported that  
36 they had just mobilised. Similarly, Brady<sup>(39)</sup> found that 16% (59/362) of patients reported that  
37 they had just mobilised. Similarly, Brady<sup>(39)</sup> found that 16% (59/362) of patients reported that  
38 they had just mobilised. Similarly, Brady<sup>(39)</sup> found that 16% (59/362) of patients reported that  
39 they had just mobilised. Similarly, Brady<sup>(39)</sup> found that 16% (59/362) of patients reported that  
40 they had just mobilised. Similarly, Brady<sup>(39)</sup> found that 16% (59/362) of patients reported that  
41 they had just mobilised. Similarly, Brady<sup>(39)</sup> found that 16% (59/362) of patients reported that  
42 they had just mobilised. Similarly, Brady<sup>(39)</sup> found that 16% (59/362) of patients reported that  
43 they had just mobilised. Similarly, Brady<sup>(39)</sup> found that 16% (59/362) of patients reported that  
44 they had just mobilised. Similarly, Brady<sup>(39)</sup> found that 16% (59/362) of patients reported that  
45 they had just mobilised. Similarly, Brady<sup>(39)</sup> found that 16% (59/362) of patients reported that  
46 they had just mobilised. Similarly, Brady<sup>(39)</sup> found that 16% (59/362) of patients reported that  
47 they had just mobilised. Similarly, Brady<sup>(39)</sup> found that 16% (59/362) of patients reported that  
48 they had just mobilised. Similarly, Brady<sup>(39)</sup> found that 16% (59/362) of patients reported that  
49 they had just mobilised. Similarly, Brady<sup>(39)</sup> found that 16% (59/362) of patients reported that  
50 they had just mobilised. Similarly, Brady<sup>(39)</sup> found that 16% (59/362) of patients reported that  
51 they had just mobilised. Similarly, Brady<sup>(39)</sup> found that 16% (59/362) of patients reported that  
52 they had just mobilised. Similarly, Brady<sup>(39)</sup> found that 16% (59/362) of patients reported that  
53 they had just mobilised. Similarly, Brady<sup>(39)</sup> found that 16% (59/362) of patients reported that  
54 they had just mobilised. Similarly, Brady<sup>(39)</sup> found that 16% (59/362) of patients reported that  
55 they had just mobilised. Similarly, Brady<sup>(39)</sup> found that 16% (59/362) of patients reported that  
56 they had just mobilised. Similarly, Brady<sup>(39)</sup> found that 16% (59/362) of patients reported that  
57 they had just mobilised. Similarly, Brady<sup>(39)</sup> found that 16% (59/362) of patients reported that  
58 they had just mobilised. Similarly, Brady<sup>(39)</sup> found that 16% (59/362) of patients reported that  
59 they had just mobilised. Similarly, Brady<sup>(39)</sup> found that 16% (59/362) of patients reported that  
60 they had just mobilised. Similarly, Brady<sup>(39)</sup> found that 16% (59/362) of patients reported that

Palmerola<sup>(36)</sup> found adherence to IPC after caesarean delivery was 79.5% (233/293). Of the 60 non-  
adherent patients, 62% (37/60) had the IPC machine and sleeves in the room but they were not  
applied and 38% (23/60) had it discontinued due to "liberal standards for mobilisation". A study by  
Obi<sup>(35)</sup> previously discussed in relation to 'patient discomfort' found that problems with mobilising  
were reported less using a new machine compared to a standard one (71% vs. 29%). Garcia Olivares<sup>(40)</sup>  
found that complete bed rest for >2 days resulted in improved appropriateness of prophylaxis (OR  
0.6) with similar findings reported for mechanical ventilation (OR 0.7).

### *4. Equipment supply and demand*

1  
2  
3 Three studies<sup>(28,33,39)</sup> highlighted that equipment supply and demand could affect adherence. Brady<sup>(39)</sup>  
4 identified that part of the IPC device was not present in the room in 13% (49/362) of non-adherent  
5 episodes although reasons why were not explored. Similar findings by Ritsema<sup>(28)</sup> found that the  
6 second most commonly report reason for non-adherence was no machine or sleeves being available  
7 to the patient (22/100 questionnaire responses). As previously discussed within 'healthcare  
8 professionals knowledge and behaviours', a study by Gardiner<sup>(33)</sup> revealed that of 250 patients who  
9 were non-adherent, 39% (97/250) did not have part of the equipment in the room. This same study  
10 found that adherence increased from 26% to 44% through an educational intervention and making  
11 IPC machines widely available instead of difficult to obtain for use.  
12  
13  
14  
15  
16  
17  
18  
19

## 20 5. Guidelines

21 The use of guidelines for VTE prevention was identified as a factor that could affect adherence in three  
22 studies<sup>(40,41,43)</sup>. Garcia Olivares<sup>(40)</sup> used an electronic questionnaire to investigate inappropriateness of  
23 VTE prophylaxis (all types) on a single day across multiple intensive care units (ICUs). A total of 777  
24 patients across 73 ICUs were included: the use of a protocol reduced inappropriate VTE prevention  
25 prescribing (OR 0.6) as well as a VTE risk scoring system (OR 0.4). Yammamoto<sup>(41)</sup> obtained data from  
26 99 ICUs and included 470 patients in their analysis. Hospitals using protocols had higher rates of  
27 prophylaxis provision than those who did not (89% vs. 80%) and this difference was mainly due to the  
28 increase in the combined use of anti-embolic stockings and IPC (26% vs. 15%). A similar effect was  
29 demonstrated by Maffei<sup>(43)</sup> who retrospectively analysed the accuracy of prescribing of VTE  
30 prophylaxis after the implementation of guidelines. Compared to before the implementation of  
31 guidelines, prescribing of IPC therapy increased from 26% to 32% after.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

## 42 6. Intensive care context

43 Care provision in the ICU context was identified by two studies as having an impact on adherence<sup>(26,29)</sup>.  
44 Comerota<sup>(26)</sup> examined 138 patients and found that adherence in the ICU setting was higher than  
45 elsewhere in the hospital (78% vs. 48%) but did not investigate reasons for this. A study by Bockheim<sup>(29)</sup>  
46 found adherence in the ICU context was 69% (52/75) compared to 40% (30/75) outside of the ICU.  
47 The authors concluded the reasons for this were likely to be multifactorial they did not empirically  
48 determine what these factors might be.  
49  
50  
51  
52  
53  
54

## 55 7. Computer-assisted prescribing

56 Computer-assisted prescribing was reported as a factor affecting adherence in two studies<sup>(34,37)</sup>.  
57 Chen<sup>(37)</sup> examined the long-term impact of automatic pre-orders for IPC on an electronic prescription  
58  
59  
60

1  
2  
3 system. Prior to the intervention, prescribing of IPC was carried out on 46% (denominator not  
4 reported) of patients. One year later, this had increased to 78% (59/76). IPC was only present in 71%  
5 (42/59) of patients who had been prescribed IPC and was only being used by 45% (19/42) of those  
6 patients. The authors concluded that the intervention had successfully increased prescribing of IPC  
7 but not overall adherence.  
8  
9

10  
11 Novis<sup>(34)</sup> utilised a similar approach but did not assess the impact of adherence to IPC at a patient level.  
12 Computer generated suggestions of pre-operative prophylaxis were provided to the clinician as a  
13 result of information entered about the risk of VTE to the patient. The result was a 40% increase in  
14 prescribing of IPC from 215 to 301 patients with an active prescription.  
15  
16  
17

### 18 19 20 *8. Patient knowledge*

21 A study by Kim<sup>(27)</sup> concluded that the information needs of patients were a factor affecting adherence.  
22 An initial survey found that 59% (32/54) of patients did not have IPC applied when prescribed. Several  
23 clinician-focused interventions were conducted, and a survey of patients a year later found that 62%  
24 (41/66) of patients requiring IPC therapy did not have it applied. From this, thirty percent (11/37) of  
25 patients reported that they did not know what a DVT is and 62% (23/37) reported that they had not  
26 been educated about IPC. The authors conclude that a lack of education is an important barrier to  
27 adherence however evidence to demonstrate that increasing education results in improved  
28 adherence was not presented.  
29  
30  
31  
32  
33  
34

### 35 36 37 **Quality Assessment**

38 Seventeen<sup>(26-41,43)</sup> (out of the 20) articles included in the review were observational in nature. All of  
39 these studies (n=17) measured adherence to IPC by direct observation of researchers rather than  
40 based on self-report, which could have been subject to recall bias. Eight of these studies measured  
41 adherence twice daily<sup>(25,26,28,29,33,37,39,42)</sup>, three had a single observation point (the first day post  
42 operatively<sup>(31,36)</sup> and not reported<sup>(30)</sup>), one<sup>(35)</sup> had hourly monitoring across a 24 hour period, and  
43 one<sup>(17)</sup> did not report when they observed adherence, only that they did this. In addition to direct  
44 observations, data on factors affecting adherence using patient surveys was performed in eight  
45 studies<sup>(17,25,27,28,30,31,39,42)</sup> and indirect indicators such as the effect of a change in device type or the  
46 result of a guideline implementation was used in seven studies<sup>(26,29,34,35,37,43)</sup>. The three RCTs<sup>(17,25,42)</sup>  
47 collected data on adherence using researcher observations and patient surveys  
48  
49  
50  
51  
52  
53  
54

55  
56  
57 Over half of the articles<sup>(25,27-34,36,37,39,40)</sup> (n=13) focused on factors affecting adherence to IPC as a  
58 primary outcome. The remaining studies<sup>(17,26,35,38,41-43)</sup> (n=7) investigated as the safety and  
59  
60

1  
2  
3 effectiveness of IPC as their main outcome. As a result of these investigations, these studies also  
4 provided data on factors affecting adherence (though this was not their aim). It is difficult to determine  
5 whether additional factors may have been uncovered from these studies (i.e. that are not reported in  
6 our findings) if the authors had specifically set out to examine how adherence to IPC could be affected.  
7  
8 Taken collectively, the patient sample sizes for each study ranged from between 67(35) to 800(34)  
9 with the majority of studies being based on over 100 patients. Articles we included were published  
10 across a 27-year period.  
11  
12  
13  
14  
15  
16  
17

## 18 Discussion

19  
20 This paper presents the findings of a systematic review on factors affecting adherence to IPC in the  
21 inpatient setting. In total eight factors were identified that affected adherence, with patient  
22 discomfort related to wearing the IPC device being most commonly reported and issues related to  
23 computer assisted prescribing and patients' knowledge of IPC being the least frequently reported. The  
24 majority of factors delineated (such as patient discomfort, mobilising, healthcare professional  
25 knowledge and behaviours, patient knowledge, equipment supply and demand) acted as a barrier to  
26 adherence to IPC. However, some evidence points to specific facilitators of adherence (for example  
27 the use of guidelines and protocols and computer-assisted prescribing).  
28  
29  
30  
31  
32  
33  
34

35 There are several important implications of this work. First, discomfort with the IPC device was a  
36 considerable cause for non-adherence. The development and/or use of new or alternative IPC devices  
37 should be considered when addressing adherence issues. Research has demonstrated that using  
38 methods to systematically incorporate the user perspective early in the design process can result in  
39 the development of a device which is safe, effective and used by the patient<sup>(44)</sup>. Research more widely  
40 in the field that examined the use of a modern IPC device demonstrates that it is possible to develop  
41 comfortable devices<sup>(45)</sup> with 86% (26/30) of patients reporting it was comfortable and that they would  
42 use it again if required. Two studies<sup>(35,42)</sup> within this review reported adherence levels when studying  
43 different machine designs and one study focused on the length of IPC sleeve<sup>(30)</sup> and its effect on  
44 adherence with knee length sleeves being adhered to to a greater degree. The same study found  
45 similar results with the length of AES and this was also found in a review of adherence in surgical  
46 specialities<sup>(46)</sup>. There is therefore scope for further research using a randomised control study design  
47 to assess widely used IPC machines, the length of sleeves and the effect both factors have on  
48 adherence, particularly in relation to comfort.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Second, and related to the above point, mobility was often reported as a barrier to adherence. One  
4 likely explanation for this could be that it was uncomfortable for patient to mobilise while wearing the  
5 device, so for this reason it was removed. Evidence<sup>(26,29)</sup> from our review revealed that adherence was  
6 less of an issue for those patients that were unable to move around. However, IPC is designed to  
7 promote blood flow during immobility and if a patient is mobile, it could be concluded that IPC is no  
8 longer required and thus would not meet the criteria for data being collected as adherent or not.  
9 While this is a point that warrants further investigation, our findings suggest this could be why  
10 mobilisation (perhaps wrongly so) was identified as an adherence-related issue. Within the wider  
11 literature, a systematic review<sup>(47)</sup> on the definition used for immobility within thromboprophylaxis  
12 studies concluded that a lack of consistency in the definition of immobility may contribute to the  
13 underutilisation of thromboprophylaxis in clinical practice. In our review, the definition of mobility to  
14 the extent that IPC was no longer required was not stated by any of our included studies. In place of  
15 a widely agreed consensus, an institution-wide definition of mobility could assist individual hospitals  
16 to ensure that best practice is promoted in relation to IPC adherence.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

28 Third, we found that HCP knowledge and beliefs could contribute to non-adherence. It is not clear  
29 from our studies whether on those occasions when an IPC device was not fitted, the reasons related  
30 more to the HCP not knowing they needed to do this, whether they simply forget, or whether there  
31 has been some other unknown issue. While this warrants further investigations, there are some  
32 relatively straightforward strategies that could be put in place, based on our preliminary findings. For  
33 example, prompts and educational leaflets could be distributed on the hospital wards to remind HCPs  
34 when the use of IPC is required and why this is important. Training is essential if optimal adherence  
35 levels are to be achieved and maintained. Equally, ensuring the layout of the ward allows easy  
36 accessibility of equipment (such as IPC) is also important, particularly, given our review revealed this  
37 to be a determinant of adherence.  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 Finally, our review revealed that the use of guidelines and how they are incorporated into electronic  
48 prescribing systems could act as a facilitator to adherence. Similar findings (which examined, in part  
49 the use of pre-printed orders) have been reported in a review of the barriers and facilitators to  
50 adherence to chemical thromboprophylaxis<sup>(48)</sup> within the ICU setting. Additional research that  
51 examined how electronic prescribing can lead to a reduction in errors, identified an absolute risk  
52 reduction of up to 30%<sup>(49)</sup>. Together with the evidence in this review, it could be concluded that if IPC  
53 prescribing is included in electronic prescribing systems, improvements in adherence to guidelines  
54 may be achieved.  
55  
56  
57  
58  
59  
60

### Strengths and limitations

There are several strengths of this review. To the best of our knowledge, this is the only paper of its kind to systematically review the evidence on factors affecting adherence to IPC across medical and surgical specialities. Wider research within the field that has reviewed the literature relating to IPC adherence found a median adherence rate of 78%<sup>(20)</sup>. The review concluded that strategies to improve adherence are required. Our review helps to address this important gap in the evidence, shedding light on potential indicators of issue.

The evidence in our review was derived from articles that provided an actual measure of adherence in clinical settings and the subsequent factors that could help to explain these adherence rates. Many of the factors relating to adherence were based on direct observation rather than self-report.

A caveat to mention when interpreting our findings is that while data were based on quite a large body of evidence, there were differing (and sometimes low) sample sizes as well as different aims and methodologies and countries and settings of focus. Included studies were also spread over a long period of time (twenty-seven years), in which policies and procedures around IPC may have changed. Equally most of the factors affecting adherence were only reported a few times. While, admittedly this was not the primary aim of the studies included in our review, but rather was reported as secondary finding in relation to explaining adherence rates, further work is required to understand the relative strength of the evidence. Nonetheless, this review provides a useful first step to delineating important (and perhaps otherwise empirically unknown) factors affecting adherence to IPC. These findings could be used to help inform, implement and evaluate the use of specific strategies to overcome factors causing adherence-related issues.

### Conclusion

This systematic review set out to uncover the factors that affect adherence to IPC for VTE prevention in acute care. Gaining this understanding is critical in order to develop interventions, strategies and policies which are accurately targeted at meeting the challenges of improving adherence<sup>(21)</sup>. While our review has addressed an important gap in the evidence base and taken the first steps to understanding reasons why non-adherence to IPC may occur, it is clear more research is required in this area to further understand the relative strength of the evidence, so that effective strategies to overcome barriers to adherence can be sought.

## References

- (1) Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. *Arch Intern Med* 1998;158(6):585-593.
- (2) NHS Digital. 5.1 Deaths from venous thromboembolism (VTE) related events within 90 days post discharge from hospital. 2019; Available at: <https://digital.nhs.uk/data-and-information/publications/clinical-indicators/nhs-outcomes-framework/current/domain-5-treating-and-caring-for-people-in-a-safe-environment-and-protecting-them-from-avoidable-harm-nof/5-1-deaths-from-venous-thromboembolism-vte-related-events-within-90-days-post-discharge-from-hospital>. Accessed 18/10/2019, 2019.
- (3) Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ3. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. *Arch Intern Med* 2000 Mar 27;160(6):809-815.
- (4) Heit JA, O'Fallon W, Michael Petterson TM, Lohse CM, Silverstein MD, Mohr DN, et al. Relative Impact of Risk Factors for Deep Vein Thrombosis and Pulmonary Embolism: A Population-Based Study. *Arch Intern Med* 2002 June 10;162(11):1245-1248.
- (5) Jha AK, Larizgoitia I, Audera-Lopez C, Prasopa-Plaizier N, Waters H, Bates DW. The global burden of unsafe medical care: analytic modelling of observational studies. *BMJ Qual Saf* 2013 Oct;22(10):809-815.
- (6) All-Party Parliamentary Thrombosis Group. All-Party Parliamentary Thrombosis Group Annual Review 2017. 2017.
- (7) Grosse SD, Nelson RE, Nyarko KA, Richardson LC, Raskob GE. The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs. *Thromb Res* 2016 Jan;137:3-10.
- (8) Noble S, Lewis R, Whithers J, Lewis S, Bennett P. Long-term psychological consequences of symptomatic pulmonary embolism: a qualitative study. *BMJ Open* 2014 Apr 02;4(4):e004561.
- (9) Hunter R, Lewis S, Noble S, Rance J, Bennett PD. "Post-thrombotic panic syndrome": A thematic analysis of the experience of venous thromboembolism. *British journal of health psychology* 2017;22(1):8-25.
- (10) Roberts LN, Durkin M, Arya R. Annotation: Developing a national programme for VTE prevention. *Br J Haematol* 2017 07;178(1):162-170.

- 1  
2  
3 (11) Maynard GA. Preventing hospital-associated venous thromboembolism: a guide for effective  
4 quality improvement. : Agency for Healthcare Research and Quality, US Department of Health  
5 and ...; 2016.  
6  
7  
8 (12) Barco S, Mahmoudpour SH, Valerio L, Klok FA, Münzel T, Middeldorp S, et al. Trends in mortality  
9 related to pulmonary embolism in the European Region, 2000–15: analysis of vital registration data  
10 from the WHO Mortality Database. *The Lancet Respiratory Medicine* 2019.  
11  
12 (13) NICE. Clinical Guideline 92 Venous thromboembolism: reducing the risk: Reducing the risk of  
13 venous thromboembolism (deep vein thrombosis and pulmonary embolism). 2010; Available at:  
14 <https://www.nice.org.uk/guidance/>. Accessed 11/05/2018.  
15  
16 (14) Sigel B, Edelstein AL, Savitch L, Hasty JH, Felix WR. Type of compression for reducing venous  
17 stasis: a study of lower extremities during inactive recumbency. *Archives of Surgery*  
18 1975;110(2):171-175.  
19  
20 (15) Jacobs D.G., Piotrowski J.J., Hoppensteadt D.A., Salvator A.E., Fareed J., Browder W., et al.  
21 Hemodynamic and fibrinolytic consequences of intermittent pneumatic compression: Preliminary  
22 results. *Journal of Trauma - Injury, Infection and Critical Care* 1996 1996;40(5):710-717.  
23  
24 (16) Comerota A.J., Chouhan V., Harada R.N., Sun L., Hosking J., Veermansunemi R., et al. The  
25 fibrinolytic effects of intermittent pneumatic compression mechanism of enhanced fibrinolysis. *Ann*  
26 *Surg* 1997 1997;226(3):306-314.  
27  
28 (17) Vignon P., Dequin P.F., Renault A., Mathonnet A., Paleiron N., Imbert A., et al. Intermittent  
29 pneumatic compression to prevent venous thromboembolism in patients with high risk of bleeding  
30 hospitalized in intensive care units: The CIREA1 randomized trial. *Intensive Care Med* 2013 May  
31 2013;39(5):872-880.  
32  
33 (18) Kakkos SK, Caprini JA, Geroulakos G, Nicolaidis AN, Stansby G, Reddy DJ, et al. Combined  
34 intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous  
35 thromboembolism. *Cochrane Database Syst Rev* 2016 Sep 7;9:CD005258.  
36  
37 (19) Pavon JM, Adam SS, Razouki ZA, McDuffie JR, Lachiewicz PF, Kosinski AS, et al. Effectiveness of  
38 Intermittent Pneumatic Compression Devices for Venous Thromboembolism Prophylaxis in High-Risk  
39 Surgical Patients: A Systematic Review. *J Arthroplasty* 2016 Feb;31(2):524-532.  
40  
41 (20) Craigie S., Tsui J.F., Agarwal A., Sandset P.M., Guyatt G.H., Tikkinen KAO. Adherence to  
42 mechanical thromboprophylaxis after surgery: A systematic review and meta-analysis. *Thromb Res*  
43 2015 01 Oct 2015;136(4):723-726.  
44  
45 (21) WHO. Adherence to long-term therapies. Evidence for Action. World Health Organisation  
46 2003:7.  
47  
48 (22) Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the  
49 quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials* 1996;17(1):1-  
50 12.  
51  
52 (23) Wells G. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non randomised studies  
53 in meta-analyses. [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp) 2001.  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3 (24) Blaxter M. Criteria for the evaluation of qualitative research papers. *Medical Sociology News* 1996;22(1):68-71.  
4  
5  
6 (25) Maxwell GL, Synan I, Hayes RP, Clarke-Pearson DL. Preference and compliance in postoperative  
7 thromboembolism prophylaxis among gynecologic oncology patients. *Obstetrics & Gynecology*  
8 2002;100(3):451-455.  
9  
10 (26) Comerota AJ, Katz ML, White JV. Why does prophylaxis with external pneumatic compression  
11 for deep vein thrombosis fail? *The American journal of surgery* 1992;164(3):265-268.  
12  
13 (27) Kim PS, Probeck K, Elitharp D, Shang T, Gasparis AP, Labropoulos N. The staff and patient  
14 perspectives on compliance with mechanical prophylaxis for venous thromboembolism. *Journal of*  
15 *Vascular Surgery: Venous and Lymphatic Disorders* 2018;6(4):441-448.  
16  
17 (28) Ritsema DF, Watson JM, Stiteler AP, Nguyen MM. Sequential compression devices in  
18 postoperative urologic patients: an observational trial and survey study on the influence of patient  
19 and hospital factors on compliance. *BMC Urol* 2013 Apr 11;13:20.  
20  
21 (29) Bockheim H.M., McAllen K.J., Baker R., Barletta JF. Mechanical prophylaxis to prevent venous  
22 thromboembolism in surgical patients: A prospective trial evaluating compliance. *J Crit Care* 2009  
23 June 2009;24(2):192-196.  
24  
25 (30) Brady D., Raingruber B., Peterson J., Varnau W., Denman J., Resuello R., et al. The use of knee-  
26 length versus thigh-length compression stockings and sequential compression devices. *Crit Care Nurs*  
27 Q 2007 July/September 2007;30(3):255-262.  
28  
29 (31) Cindolo L., Salzano L., Mirone V., Imbimbo C., Longo N., Kakkos S.K., et al. Thromboprophylaxis  
30 in radical retropubic prostatectomy: Efficacy and patient compliance of a dual modality. *Urol Int*  
31 2009 July 2009;83(1):12-18.  
32  
33 (32) Elpern E, Killeen K, Patel G, Senecal PA. The application of intermittent pneumatic compression  
34 devices for thromboprophylaxis: AN observational study found frequent errors in the application of  
35 these mechanical devices in ICUs. *Am J Nurs* 2013 quiz 37; Apr;113(4):30-36.  
36  
37 (33) Gardiner DA, Kelly B. Improving rates of intermittent pneumatic compression therapy  
38 utilization. *Hosp Pract (Minneap)* 2013 Aug;41(3):40; Aug-47.  
39  
40 (34) Novis SJ, Havelka GE, Ostrowski D, Levin B, Blum-Eisa L, Prystowsky JB, et al. Prevention of  
41 thromboembolic events in surgical patients through the creation and implementation of a  
42 computerized risk assessment program. *J Vasc Surg* 2010 Mar;51(3):648-654.  
43  
44 (35) Obi A.T., Alvarez R., Reames B.N., Moote M.J., Thompson M.A., Wakefield T.W., et al. A  
45 prospective evaluation of standard versus battery-powered sequential compression devices in  
46 postsurgical patients. *Am J Surg* 2015 01 Apr 2015;209(4):675-681.  
47  
48 (36) Palmerola K.L., Brock C.O., D'Alton M.E., Friedman AM. Compliance with mechanical venous  
49 thromboprophylaxis after cesarean delivery. *Journal of Maternal-Fetal and Neonatal*  
50 *Medicine* 2016 01 Oct 2016;29(19):3072-3075.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 (37) Chen M, Sarnoski KA, Jacques LH, Klatt T, Palatnik A. Sequential compression device compliance  
4 in pregnant women requiring antepartum admission. *The Journal of Maternal-Fetal & Neonatal*  
5 *Medicine* 2019;1-7.  
6

7  
8 (38) Cornwell EE3, Chang D, Velmahos G, Jindal A, Baker D, Phillips J, et al. Compliance with  
9 sequential compression device prophylaxis in at-risk trauma patients: a prospective analysis. *Am*  
10 *Surg* 2002 May;68(5):470-473.  
11

12 (39) Brady MA, Carroll AW, Cheang KI, Straight C, Chelmow D. Sequential compression device  
13 compliance in postoperative obstetrics and gynecology patients. *Obstet Gynecol* 2015 Jan;125(1):19-  
14 25.  
15

16 (40) GarciaOlivares P., Guerrero J.E., Keough E., Galdos P., Carriedo D., Murillo F., et al. Clinical  
17 factors associated with inappropriate prophylaxis of venous thromboembolic disease in critically ill  
18 patients. A single day cross-sectional study. *Thromb Res* 2016 01 Jul 2016;143:111-117.  
19

20 (41) Yamamoto T., Nakamura M., Kuroiwa M., Tanaka K. Current prevention practice for venous  
21 thromboembolism in Japanese intensive care units. *Journal of Anesthesia* 2013 December  
22 2013;27(6):931-934.  
23

24 (42) Sobieraj-Teague M, Hirsh J, Yip G, Gastaldo F, Stokes T, Sloane D, et al. Randomized controlled  
25 trial of a new portable calf compression device (Venowave) for prevention of venous thrombosis in  
26 high-risk neurosurgical patients. *J Thromb Haemost* 2012 Feb;10(2):229-235.  
27

28 (43) Maffei F.H.A., Sato A.C., Filho F.T., da Silva S.C., Atallah A. Effect of the implementation of a  
29 guideline for venous thromboembolism prophylaxis in surgical patients. *Rev Assoc Med Bras* 2009  
30 2009;55(5):587-592.  
31

32 (44) Martin JL, Clark DJ, Morgan SP, Crowe JA, Murphy E. A user-centred approach to requirements  
33 elicitation in medical device development: A case study from an industry perspective. *Appl Ergon*  
34 2012;43(1):184-190.  
35

36 (45) Guimicheva B, Patel JP, Roberts LN, Subramanian D, Arya R. Women's views, adherence and  
37 experience with postnatal thromboprophylaxis. *Thromb Res* 2019;173:85-90.  
38

39 (46) Wade R, Research Fellow, Paton F, Research Fellow, Woolacott, Nerys B.Sc Senior Research  
40 Fellow. Systematic review of patient preference and adherence to the correct use of graduated  
41 compression stockings to prevent deep vein thrombosis in surgical patients. *J Adv Nurs* 2017  
42 February;73(2):336-348.  
43

44 (47) Emed JD, Morrison DR, Des Rosiers L, Kahn SR. Definition of immobility in studies of  
45 thromboprophylaxis in hospitalized medical patients: a systematic review. *Journal of Vascular*  
46 *Nursing* 2010;28(2):54-66.  
47

48 (48) Cook D, Duffett M, Lauzier F, Ye C, Dodek P, Paunovic B, et al. Barriers and facilitators of  
49 thromboprophylaxis for medical-surgical intensive care unit patients: a multicenter survey. *J Crit*  
50 *Care* 2014;29(3):471. e1-471. e9.  
51

52 (49) Dalton K, O'Brien G, O'Mahony D, Byrne S. Computerised interventions designed to reduce  
53 potentially inappropriate prescribing in hospitalised older adults: a systematic review and meta-  
54 analysis. *Age Ageing* 2018;47(5):670-678.  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure 1: Prisma flow chart of search results retrieved 30<sup>th</sup> May 2019**

For peer review only

**Table 1: Characteristics of included studies**

Author	Study design	Setting	Studies main objective	Focus was adherence barriers / facilitators?	Sample size	Participants (mean age)	Country
Bockheim 2009 (29)	Prospective observational	Critical care & Ward care	Comparison of IPC compliance between ICU and non ICU areas	Yes	150	Female 73, Male 77 (62)	USA
Brady 2007 (30)	Prospective observational	Acute nursing care wards	To assess comfort and fit and compliance of knee vs thigh length IPC	Yes	137	Female 72, Male 65 (55)	USA
Brady 2015 (39)	Prospective observational	Caesarean or gynaecological surgery	To assess impact of education on compliance to IPC	Yes	228	Female 59 (38)	USA
Chen 2019 (37)	Prospective observational	Obstetrics	Assess the effectiveness of an intervention in improving compliance to IPC	Yes	76	Female 76 (28)	USA
Cindolo 2009 (31)	Prospective observational	Radical retropubic prostatectomy surgery	To assess acceptability and satisfaction to IPC	Yes	184	Male 184 (69)	USA
Comerota 1992 (26)	Prospective observational	Critical care & Ward care	Comparison of IPC compliance between ICU and non ICU areas	No	138	Not reported	USA
Cornwell 2002 (38)	Prospective observational	Surgical trauma	To assess compliance of IPC in trauma patients	No	227	Female 39, Male 188 (37)	USA
Elphern 2013 (32)	Prospective observational	Critical care	Identifying reasons for errors in the application of IPC	Yes	123	Female 42, Male 54	USA
García-Olivares 2016 (40)	Prospective observational	Critical care	Factors associated with inadequate thromboprophylaxis in critically ill patients	Yes	777	Female 270, Male 507 (61)	Spain
Gardiner 2013 (33)	Prospective observational	Surgical wards	Quality improvement to increase IPC compliance	Yes	339	Not reported	USA
Kim 2018 (27)	Cohort Study	Surgical, medical & critical care	Accuracy of VTE assessment, compliance to IPC and effect of education on compliance	Yes	200	Female 97, Male 103 (62)	USA
Maffei 2009 (43)	Retrospective observational	Surgical wards	Before and after study of implementation of thromboprophylaxis guidelines	No	150	Female 77, Male 73 (64)	Brazil
Maxwell 2002 (25)	Randomised controlled trial	Surgical gynaecology	To assess preference and compliance in patients receiving heparin and IPC	Yes	104	Female 104 (61)	USA
Novis 2009 (34)	Prospective observational	Surgical wards	Utilisation of DVT prophylaxis after implementation of electronic risk assessment	Yes	800	Female 15, Male 785 (64)	USA
Obi 2015 (35)	Prospective observational	Surgical wards	Comparison of compliance with a standard vs battery powered IPC device	No	67	Female 32, Male 35 (51)	USA

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

Palmerola 2015 (36)	Prospective observational	Obstetrics	Compliance with IPC after caesarean delivery	Yes	293	Female 293 (32)	USA
Ritsema 2013 (28)	Observational	Surgical wards	Study of the influence of hospital and patient factors on compliance	Yes	100	Female 24, Male 76	USA
Sobierag-Teague 2012 (42)	Randomised controlled trial	Neurosurgery	Trialling the efficacy and tolerability of an IPC device	No	75	Female 31, Male 44 (62)	Canada
Vignon 2013 (17)	Randomised controlled trial	Critical care	Effectiveness of compression stockings with and without IPC	No	205	Female 72, Male 132 (55)	France
Yamamoto 2013 (41)	Prospective observational	Critical care	Exploring the current practice of VTE prevention in Japanese ICUs	No	470	Female 168, Male 302 (65)	Japan

For peer review only

**Table 2: Factors affecting adherence**

Author	Factors	Findings
Bockheim 2009 (29)	Intensive care context	ICU has greater compliance than non-ICU
Brady 2007 (30)	Patient discomfort	Cause of non-adherence was; 39% discomfort
	Mobilisation	46% had just ambulated
	Healthcare professional knowledge and behaviours	13% the nurse had not reapplied the IPC after transfer from another unit
Brady 2015 (39)	Healthcare professional knowledge and behaviours	When asked, 23% of patients said nurses instruction to not wear
	Equipment supply and demand	13% did not have part of the device in the room
	Mobilisation	17% said they had just returned to bed, 16% walking around, 7% just about to walk around
	Patient discomfort	15% of patients said the IPC was uncomfortable
Chen 2019 (37)	Computer assisted prescribing	A pre-checked electronic order increased prescribing adherence from 46% to 77%
Cindolo 2009 (31)	Patient discomfort	Noise and insomnia were reported as being a negative experience in 23% and 44% of cases respectively. Authors state these issues were reasons why 3% had IPC removed early
Comerota 1992 (26)	Intensive care context	ICU has greater compliance than non-ICU
Cornwell 2002 (38)	Healthcare professional knowledge and behaviours	Compliance rate of 53%. Information reported about non-compliance was that the device was not in place (95%)
Elphern 2013 (32)	Healthcare professional knowledge and behaviours	In 51% of non-adherence observed, IPC sleeves were not correctly applied and 24% the machine was not switched on
García-Olivares 2016 (40)	Mobilisation	Patients with invasive mechanical ventilation and complete bedrest had greater compliance
	Guidelines	use of a protocol and risk scoring system led to decreased risk of inappropriate VTE prophylaxis
Gardiner 2013 (33)	Equipment supply and demand	In 38% of non-adherent cases the IPC machine was not in the room, locating IPC machines in rooms resulted in adherence from 26% to 44%
	Healthcare professional knowledge and behaviours	A nursing knowledge and beliefs survey yields information about barriers that nurses bring to the use of IPC
Kim 2018 (27)	Knowledge	40% overall non-adherence to IPC. Of these, 40% said that no one informed them they needed to keep IPC on
	Patient discomfort	40% overall non-adherence to IPC, 33% said this was due to discomfort
Maffei 2009 (43)	Guidelines	After guidelines were introduced, IPC prescription increased from 26% to 32%
Maxwell 2002 (25)	Healthcare professional knowledge and behaviours	Of 736 observations, non-compliance was noted in 2.7% of cases and this was related to the machine not being switched on
Novis 2009 (34)	Computer assisted prescribing	Electronic suggestion of thromboprophylaxis increased the use of IPC from 50% to 63%
	Device related	A battery powered device facilitated adherence through enabling mobilisation
Obi 2015 (35)	Patient discomfort	A new machine design led to fewer reports of patient discomfort (33% vs 13%)
	Mobilisation	Problems with mobilisation were less using a new machine (71% vs 29%)
Palmerola 2015 (36)	Mobilisation	38% of patients classed as non-adherent to IPC therapy had it discontinued due to liberal standards for ambulation
Ritsema 2013 (28)	Mobilisation	Not replaced after mobilising accounted for 50% of non-compliant observations
	Equipment supply and demand	Lack of machine or cuffs accounted for 22% of non-adherence
	Patient discomfort	Patient discomfort accounted for 19% of non-adherence
Sobierag-Teague 2012 (42)	Patient discomfort	48% of users discontinued the device at night. Comfort related issues discussed but not explicitly linked to non-adherence

Vignon 2013 (17)	Patient discomfort	7% non-compliance in the AES + IPC group. IPC was discontinued due to discomfort, noise and restlessness
Yamamoto 2013 (41)	Guidelines	Combined AES and IPC mechanical prophylaxis was higher in units with a protocol than without (88% vs 80%)

For peer review only

Figure 1: PRISMA flow chart of search results retrieved 30<sup>th</sup> May 2019




Figure 1

169x156mm (120 x 120 DPI)



## Supplementary file

*Intermittent pneumatic compression for venous thromboembolism prevention: a systematic review on factors affecting adherence*

### Search strategy

Population	Intervention	Comparison	Outcomes
Intermittent pneumatic compression OR Sequential compression	Interven\$ OR Strateg\$ OR Guideline\$ OR Educat\$ OR Inform\$ OR PDSA OR Plan do study act OR Improv\$ OR Implement\$ OR Toleran\$ OR Aware\$ OR Present\$ OR Program\$ OR Plan\$ OR Approach\$ OR Project\$ OR Procedure\$ OR Polic\$ OR Method\$ OR Design\$ OR Action\$ OR Part\$ OR Involv\$ OR Practice\$ OR Process\$ OR System\$ OR Technique\$ OR Scheme\$	N/A	Complian\$ OR Adhere\$ OR Efficacy OR Effective\$ OR Outcome\$ OR Success\$ OR Fail\$ OR Fidelity

### Medline Search

1. (Complian\$ or Adhere\$ or Efficacy or Effective\$ or Outcome\$ or Success\$ or Fail\$ or Fidelity).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
2. (Interven\$ or Strateg\$ or Guideline\$ or Educat\$ or Inform\$ or PDSA or Plan do study act or Improv\$ or Implement\$ or Toleran\$ or Aware\$ or Present\$ or Program\$ or Plan\$ or Approach\$ or Project\$ or Procedure\$ or Polic\$ or Method\$ or Design\$ or Action\$ or Part\$ or Involv\$ or Practice\$ or Process\$ or System\$ or Technique\$ or Scheme\$).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
3. (Intermittent pneumatic compression or Sequential compression).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
4. 1 and 2 and 3

### Filters

English language  
Dates - January 1960 – May 2019

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# Reporting checklist for systematic review and meta-analysis.

Based on the PRISMA guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA reporting guidelines, and cite them as:

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

	Reporting Item	Page Number
<b>Title</b>		
	<a href="#">#1</a> Identify the report as a systematic review, meta-analysis, or both.	1

## Abstract

1	Structured	<a href="#">#2</a>	Provide a structured summary including, as applicable:	2
2				
3	summary		background; objectives; data sources; study eligibility criteria,	
4			participants, and interventions; study appraisal and synthesis	
5			methods; results; limitations; conclusions and implications of	
6			key findings; systematic review registration number	
7				
8				
9				
10				
11				
12				
13	<b>Introduction</b>			
14				
15				
16	Rationale	<a href="#">#3</a>	Describe the rationale for the review in the context of what is	3
17			already known.	
18				
19				
20				
21				
22	Objectives	<a href="#">#4</a>	Provide an explicit statement of questions being addressed	4
23			with reference to participants, interventions, comparisons,	
24			outcomes, and study design (PICOS).	
25				
26				
27				
28				
29	<b>Methods</b>			
30				
31				
32	Protocol and	<a href="#">#5</a>	Indicate if a review protocol exists, if and where it can be	4
33	registration		accessed (e.g., Web address) and, if available, provide	
34			registration information including the registration number.	
35				
36				
37				
38				
39				
40	Eligibility criteria	<a href="#">#6</a>	Specify study characteristics (e.g., PICOS, length of follow-up)	4
41			and report characteristics (e.g., years considered, language,	
42			publication status) used as criteria for eligibility, giving rational	
43				
44				
45				
46				
47				
48	Information	<a href="#">#7</a>	Describe all information sources in the search (e.g., databases	4
49	sources		with dates of coverage, contact with study authors to identify	
50			additional studies) and date last searched.	
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1	Search	<a href="#">#8</a>	Present full electronic search strategy for at least one	5
2			database, including any limits used, such that it could be	
3			repeated.	
4				
5				
6				
7				
8	Study selection	<a href="#">#9</a>	State the process for selecting studies (i.e., for screening, for	5
9			determining eligibility, for inclusion in the systematic review,	
10			and, if applicable, for inclusion in the meta-analysis).	
11				
12				
13				
14				
15				
16	Data collection	<a href="#">#10</a>	Describe the method of data extraction from reports (e.g.,	5
17	process		piloted forms, independently by two reviewers) and any	
18			processes for obtaining and confirming data from investigators.	
19				
20				
21				
22				
23				
24	Data items	<a href="#">#11</a>	List and define all variables for which data were sought (e.g.,	Supp.
25			PICOS, funding sources), and any assumptions and	file
26			simplifications made.	
27				
28				
29				
30				
31	Risk of bias in	<a href="#">#12</a>	Describe methods used for assessing risk of bias in individual	5
32	individual studies		studies (including specification of whether this was done at the	
33			study or outcome level, or both), and how this information is to	
34			be used in any data synthesis.	
35				
36				
37				
38				
39				
40				
41	Summary	<a href="#">#13</a>	State the principal summary measures (e.g., risk ratio,	n/a
42	measures		difference in means).	
43				
44				
45				
46				
47	Planned	<a href="#">#14</a>	Describe the methods of handling data and combining results	n/a
48	methods of		of studies, if done, including measures of consistency (e.g., I <sup>2</sup> )	
49	analysis		for each meta-analysis.	
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1	Risk of bias	<a href="#">#15</a>	Specify any assessment of risk of bias that may affect the	n/a
2				
3	across studies		cumulative evidence (e.g., publication bias, selective reporting	
4			within studies).	
5				
6				
7				
8				
9	Additional	<a href="#">#16</a>	Describe methods of additional analyses (e.g., sensitivity or	n/a
10				
11	analyses		subgroup analyses, meta-regression), if done, indicating which	
12			were pre-specified.	
13				
14				
15				
16	<b>Results</b>			
17				
18				
19	Study selection	<a href="#">#17</a>	Give numbers of studies screened, assessed for eligibility, and	5
20			included in the review, with reasons for exclusions at each	
21			stage, ideally with a <a href="#">flow diagram</a> .	
22				
23				
24				
25				
26				
27	Study	<a href="#">#18</a>	For each study, present characteristics for which data were	6
28				
29	characteristics		extracted (e.g., study size, PICOS, follow-up period) and	
30			provide the citation.	
31				
32				
33				
34				
35	Risk of bias	<a href="#">#19</a>	Present data on risk of bias of each study and, if available, any	n/a
36				
37	within studies		outcome-level assessment (see Item 12).	
38				
39				
40	Results of	<a href="#">#20</a>	For all outcomes considered (benefits and harms), present, for	n/a
41				
42	individual studies		each study: (a) simple summary data for each intervention	
43			group and (b) effect estimates and confidence intervals, ideally	
44			with a forest plot.	
45				
46				
47				
48				
49				
50	Synthesis of	<a href="#">#21</a>	Present the main results of the review. If meta-analyses are	7
51				
52	results		done, include for each, confidence intervals and measures of	
53			consistency.	
54				
55				
56				
57				
58				
59				
60				

1	Risk of bias	<a href="#">#22</a>	Present results of any assessment of risk of bias across	n/a
2				
3	across studies		studies (see Item 15).	
4				
5				
6	Additional	<a href="#">#23</a>	Give results of additional analyses, if done (e.g., sensitivity or	n/a
7				
8	analysis		subgroup analyses, meta-regression [see Item 16]).	
9				
10				
11				
12	<b>Discussion</b>			
13				
14				
15	Summary of	<a href="#">#24</a>	Summarize the main findings, including the strength of	10
16				
17	Evidence		evidence for each main outcome; consider their relevance to	
18				
19			key groups (e.g., health care providers, users, and policy	
20				
21			makers	
22				
23				
24				
25	Limitations	<a href="#">#25</a>	Discuss limitations at study and outcome level (e.g., risk of	10
26				
27			bias), and at review level (e.g., incomplete retrieval of identified	
28				
29			research, reporting bias).	
30				
31				
32	Conclusions	<a href="#">#26</a>	Provide a general interpretation of the results in the context of	10
33				
34			other evidence, and implications for future research.	
35				
36				
37				
38	<b>Funding</b>			
39				
40				
41	Funding	<a href="#">#27</a>	Describe sources of funding or other support (e.g., supply of	1
42				
43			data) for the systematic review; role of funders for the	
44				
45			systematic review.	
46				
47				

None The PRISMA checklist is distributed under the terms of the Creative Commons Attribution License CC-BY. This checklist can be completed online using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)